WO2007129962A1 - 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. - Google Patents

2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. Download PDF

Info

Publication number
WO2007129962A1
WO2007129962A1 PCT/SE2007/000441 SE2007000441W WO2007129962A1 WO 2007129962 A1 WO2007129962 A1 WO 2007129962A1 SE 2007000441 W SE2007000441 W SE 2007000441W WO 2007129962 A1 WO2007129962 A1 WO 2007129962A1
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
compound
phenyl
ring
formula
Prior art date
Application number
PCT/SE2007/000441
Other languages
French (fr)
Inventor
Peter Hansen
Karolina Lawitz
Matti Lepistö
Hans LÖNN
Asim Ray
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38667997&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2007129962(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AU2007248950A priority Critical patent/AU2007248950B2/en
Priority to AT07748105T priority patent/ATE459615T1/en
Priority to JP2009509485A priority patent/JP2009536196A/en
Priority to CA002649813A priority patent/CA2649813A1/en
Priority to MX2008013836A priority patent/MX2008013836A/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to BRPI0711357-9A priority patent/BRPI0711357A2/en
Priority to US12/299,879 priority patent/US7998984B2/en
Priority to EP07748105A priority patent/EP2018375B1/en
Priority to DE602007005120T priority patent/DE602007005120D1/en
Publication of WO2007129962A1 publication Critical patent/WO2007129962A1/en
Priority to IL194948A priority patent/IL194948A0/en
Priority to NO20084872A priority patent/NO20084872L/en
Priority to HK09106680.3A priority patent/HK1127599A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the present invention relates to 2-pyridone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
  • Elastases are possibly the most destructive enzymes in the body, having the ability to degrade virtually all connective tissue components.
  • the uncontrolled proteolytic degradation by elastases has been implicated in a number of pathological conditions.
  • Human neutrophil elastase (hNE) a member of the chymotrypsin superfamily of serine proteases is a 33-KDa enzyme stored in the azurophilic granules of the neutrophils. In neutrophils the concentration of NE exceeded 5 mM and its total cellular amount has been estimated to be up to 3 pg.
  • NE Upon activation, NE is rapidly released from the granules into the extracellular space with some portion remaining bound to neutrophil plasma membrane (See Kawabat et al.
  • NE is unique, as compared to other proteases (for example, proteinase 3) in that it has the ability to degrade almost all extracellular matrix and key plasma proteins (See Kawabat et al., 2002, Eur. J. Pharmacol. 451, 1-10).
  • NE is a major common mediator of many pathological changes seen in chronic lung disease including epithelial damage (Stockley, R. A. 1994, Am. J. Resp. Crit. Care Med. 150, 109-113).
  • the excessive human NE shows a prominent destructive profile and actively takes part in destroying the normal pulmonary structures, followed by the irreversible enlargement of the respiratory airspaces, as seen mainly in emphysema.
  • neutrophil recruitment into the lungs which is associated with increased lung elastase burden and emphysema in ⁇ -proteinase inhibitor-deficient mice (Cavarra et al, 1996, Lab. Invest. 75, 273-280).
  • Individuals with higher levels of the NE-OC 1 protease inhibitor complex in bronchoalveolar lavage fluid show significantly accelerated decline in lung functions compared to those with lower levels (Betsuyaku et al. 2000, Respiration, 67, 261-267).
  • Neutrophil-predominant airway inflammation and mucus obstruction of the airways are major pathologic features of COPD, including cystic fibrosis and chronic bronchitis.
  • NE impairs mucin production, leading to mucus obstruction of the airways.
  • NE is reported to increase the expression of major respiratory mucin gene, MUC5AC (Fischer, B.M & Voynow, 2002, Am. J. Respir. Cell Biol., 26, 447-452). Aerosol administration of NE to guinea pigs produces extensive epithelial damage within 20 minutes of contact (Suzuki et al., 1996, Am. J. Resp. Crit. Care Med., 153, 1405-1411).
  • NE reduces the ciliary beat frequency of human respiratory epithelium in vitro (Smallman et al., 1984, Thorax, 39, 663-667) which is consistent with the reduced mucociliary clearance that is seen in COPD patients (Currie et al., 1984, Thorax, 42, 126-130).
  • the instillation of NE into the airways leads to mucus gland hyperplasia in hamsters (Lucey et al., 1985, Am. Resp. Crit. Care Med., 132, 362-366).
  • a role for NE is also implicated in mucus hypersecretion in asthma.
  • NE In an allergen sensitised guinea pig acute asthma model an inhibitor of NE prevented goblet cell degranulation and mucus hypersecretion (Nadel et al., 1999, Eur. Resp. J., 13, 190-196). NE has been also shown to play a role in the pathogenesis of pulmonary fibrosis. NE: cti-protenase inhibitor complex is increased in serum of patients with pulmonary fibrosis, which correlates with the clinical parameters in these patients (Yamanouchi et al., 1998, Eur. Resp. J. 11, 120-125).
  • a NE s inhibitor reduced bleomycin-induced pulmonary fibrosis (Taooka et al., 1997, Am. J. Resp. Crit. Care Med., 156, 260-265). Furthermore investigators have shown that NE deficient mice are resistant to bleomycin-induced pulmonary fibrosis (Dunsmore et al., 2001, Chest, 120, 35S-36S). Plasma NE level was found to be elevated in patients who progressed to ARDS implicating the importance of NE in early ARDS disease pathogenesis. (Donnelly Q et al., 1995, Am. J. Res. Crit. Care Med., 151, 428-1433).
  • Acute lung injury caused by endotoxin in experimental animals is associated with elevated levels of NE ( Kawabata, et al., 1999, Am. J. Resp. Crit. Care, 161, 2013-2018).
  • Acute lung inflammation caused by intratracheal injection of lipopoly saccharide in mice has been shown to elevate the NE activity in bronchoalveolar lavage fluid which is significantly 0 inhibited by a NE inhibitor (Fujie et al., 1999, Eur. J. Pharmacol, 374, 117-125; Yasui, et al., 1995, Eur. Resp. J., 8, 1293-1299).
  • NE also plays an important role in the neutrophil- induced increase of pulmonary microvascular permeability observed in a model of acute lung injury caused by tumour necrosis factor ⁇ (TNF ⁇ ) and phorbol myristate acetate (PMA) in isolated perfused rabbit lungs (Miyazaki et al., 1998, Am. J. Respir. Crit. Care 5 Med., 157, 89-94).
  • TNF ⁇ tumour necrosis factor ⁇
  • PMA phorbol myristate acetate
  • NE A role for NE has also been suggested in monocrotoline-induced pulmonary vascular wall thickening and cardiac hypertrophy (Molteni et al., 1989, Biochemical Pharmacol. 38, 2411-2419).
  • Serine elastase inhibitor reverses the monocrotaline-induced pulmonary o hypertension and remodelling in rat pulmonary arteries (Cowan et al., 2000, Nature Medicine, 6, 698-702).
  • serine elastase that is, NE or vascular elastase are important in cigarette smoke-induced muscularisation of small pulmonary arteries in guinea pigs (Wright et al., 2002, Am. J. Respir. Crit. Care Med., 166, 954-960).
  • NE plays a key role in experimental cerebral ischemic damage (Shimakura et al., 2000, Brain Research, 858, 55-60), ischemia-reperfusion lung injury (Kishima et al., 1998, Ann. Thorac. Surg. 65, 913-918) and myocardial ischemia in rat heart (Tiefenbacher et al., 1997, Eur. J. Physiol., 433, 563-570).
  • Human NE levels in plasma are significantly increased above normal in inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis (Adeyemi et al., 1985, Gut, 26, 1306-1311).
  • NE has also been assumed to be involved in the pathogenesis of rheumatoid arthritis (Adeyemi et al., 1986, Rheumatol. Int., 6, 57). The development of collagen induced arthritis in mice is suppressed by a NE inhibitor (Kakimoto et al., 1995, Cellular Immunol. 165, 26-32).
  • human NE is known as one of the most destructive serine proteases and has been implicated in a variety of inflammatory diseases.
  • the important endogenous inhibitor of human NE is Ot 1 -antitrypsin.
  • the imbalance between human NE and antiprotease is believed to give rise to an excess of human NE resulting in uncontrolled tissue destruction.
  • the protease/ antiprotease balance may be upset by a decreased availability of ⁇ rantitrypsin either through inactivation by oxidants such as cigarette smoke, or as a result of genetic inability to produce sufficient serum levels.
  • Human NE has been implicated in the promotion or exacerbation of a number of diseases such as pulmonary emphysema, pulmonary fibrosis, adult respiratory distress syndrome (ARDS), ischemia reperfusion injury, rheumatoid arthritis and pulmonary hypertension.
  • diseases such as pulmonary emphysema, pulmonary fibrosis, adult respiratory distress syndrome (ARDS), ischemia reperfusion injury, rheumatoid arthritis and pulmonary hypertension.
  • R represents hydrogen or Cj-Cg alkyl
  • W represents a 5-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group; and wherein the heterocyclic ring is optionally substituted by at least one substituent selected from halogen, Cj-C 4 alkyl, Cj- C4 alkoxy, CN, OH, NO2, C1-C3 alkyl substituted by one or more F atoms, C1-C3 alkoxy substituted by one or more F atoms, NR 10 R 1 ⁇ C ⁇ CR 15 , CONR 16 R 17 , CHO, C 2 -C 4 alkanoyl, S(O) x R 18 and OSO 2 R 19 ;
  • R represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; said ring being optionally substituted with at least one substituent selected from halogen, Cj-C 4 alkyl, Cj-C 4 alkoxy, CN, OH, NO 2 , C1-C3 alkyl substituted by one
  • CONR R CHO, C 2 -C 4 alkanoyl, S(O) p R and OSO 2 R ;
  • R , R , R and R independently represent H 5 CJ-CO alkyl, formyl or C 2 -CO alkanoyl; or the group -NR R or -NR R together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O 5 S and NR 26 ;
  • R and R independently represent H, C1-C3 alkyl or Si(CH 3 ⁇ ;
  • R , R , R and R independently represent H or C1-C3 alkyl; said allcyl being optionally substituted by one or more F atoms;
  • R represents H or F
  • R represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said ring being optionally substituted with at least one substituent selected from halogen, Ci-Cg alkyl, cyano, Ci-Cg alkoxy, nitro, methylcarbonyl, NR R , C1-C3 alkyl substituted by one or more F atoms or C1-C3 alkoxy substituted by one or more F atoms;
  • R and R independently represent H or C1-C3 alkyl; said alkyl being optionally further substituted by one or more F atoms;
  • R represents hydrogen or Ci-Cg alkyl optionally substituted with at least one substituent selected from fluoro, hydroxyl and Ci-Cg alkoxy;
  • 24 X represents a single bond, O 5 NR or a group -Ci-Cg alkylene-Y-, wherein Y
  • alkylene 24 represents a single bond, oxygen atom, NR or S(0) w ; and said alkylene being optionally further substituted by OH, halogen, CN 5 NR 37 R 38 , Ci-C 3 alkoxy, CONR 39 R 40 , CO 2 R 66 ,
  • R represents a monocyclic ring system selected from i) phenoxy, ii) phenyl, iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, iv) a saturated or partially unsaturated C3-C6 cycloalkyl ring, or v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at
  • ring heteroatom selected from oxygen, S(O) 1 - and NR , wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group,
  • R represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)t or Cj-Cg alkylene optionally comprising one or more internal or terminal heteroatoms selected from oxygen, sulphur
  • the monocyclic or bicyclic ring system being optionally substituted by at least one
  • Ci-C ⁇ alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, Ci-C 6 alkoxy, Ci-C 6 alkylthio and -C(O)NR 22 R 23 ;
  • R may also represent H
  • R represents hydrogen, Ci-C 6 alkyl, Ci-C 6 alkylcarbonyl or
  • R represents hydrogen, Ci-C 6 alkyl or C3-Cg cycloalkyl; said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, Ci-C 3 alkoxy and CONR 59 R 60 ;
  • R and R independently represent H, Ci-C 6 alkyl, formyl or C2-C 6 alkanoyl
  • R and R independently represent H, Ci-C 6 alkyl, formyl, C2-C 6 alkanoyl,
  • R and R independently represent H, Ci-C 6 alkyl or C 3 -C 6 cycloalkyl
  • R 16 , R 17 , R 22 , R 23 , R 24 , R 26 , R 27 , R 31 , R 32 , R 39 , R 40 , R 42 , R 43 , R 44 , R 4S , R 46 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 62 , R 63 , R 64 , R 65 and R 66 each independently represent hydrogen or Cj-Cg alkyl;
  • an alkyl, alkenyl or alkynyl substituent group or an alkyl moiety in a substituent group may be linear or branched.
  • an alkylene group may be linear or branched.
  • the 5-membered heterocyclic ring system may have alicyclic or aromatic properties and may thus be a saturated ring system or a partially unsaturated ring system or a fully unsaturated ring system.
  • R represents hydrogen or Cj-Cg alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
  • R represents a C1-C4 or C1-C2 alkyl group, in particular a methyl group.
  • W represents a 5-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group; and wherein the heterocyclic ring is optionally substituted by at least one substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), C1-C4 alkyl (e.g. methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl or tert-butyl), C1-C4 alkoxy (e.g.
  • halogen e.g. fluorine, chlorine, bromine or iodine
  • C1-C4 alkyl e.g. methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl or tert-butyl
  • OCH 2 F, OCHF 2 , OCF 3 , OCH 2 CH 2 F, OCH 2 CF 3 , OCF 2 CF 3 , OCH(CF 3 ) 2 and OCH 2 CH 2 CF 3 ), NR 10 R 11 , C CR 15 -C(O)NR 16 R 17 , CHO, C 2 -C 4 alkanoyl (e.g. methylcarbonyl (acetyl), ethylcarbonyl, n-propylcarbonyl or isopropylcarbonyl), -S(O) x R 18 , and OSO 2 R 19 .
  • C 2 -C 4 alkanoyl e.g. methylcarbonyl (acetyl), ethylcarbonyl, n-propylcarbonyl or isopropylcarbonyl
  • -S(O) x R 18 e.g. methylcarbonyl (acetyl), ethylcarbonyl, n-
  • the group R and the 2-pyridone ring are bonded to the 5-membered ring W in a 1,2-relationship.
  • W represents a 5-membered heteroaromatic ring, especially an unsubstituted 5-membered heteroaromatic ring.
  • Examples of 5-membered heterocyclic ring systems that may be used, which may be saturated or partially unsaturated or fully unsaturated include any one of pyrrolidinyl, tetrahydrofuranyl, pyrroline, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, pyrrolidinonyl, imidazolidinonyl, oxazolyl, pyrazolyl, thiazolidinyl, thienyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, imidazolyl, furazanyl, triazolyl and tetrazolyl.
  • Preferred ring systems for group W include pyrazolyl, thiazolyl, oxazolyl and imidazolyl.
  • W represents pyrazolyl, triazolyl, thiazolyl, oxazolyl or imidazolyl.
  • R represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 (e.g. one, two or three) ring nitrogen atoms; said ring being optionally substituted with at least one (e.g. one, two, three or four) substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), C1-C4 alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl), C1-C4 alkoxy (e.g.
  • halogen e.g. fluorine, chlorine, bromine or iodine
  • C1-C4 alkyl e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl
  • C1-C4 alkoxy
  • Examples of a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms include pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl.
  • a preferred ring system is pyridinyl.
  • one substituent on the aromatic ring of group R should be in the
  • R represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; said ring being optionally substituted with at least one substituent selected from F, Cl, CN and CF 3 .
  • R represents phenyl or pyridinyl; said ring being optionally substituted with at least one substituent selected from F, Cl, CN and CF 3 .
  • R represents a phenyl or pyridinyl group optionally substituted with one or two substituents independently selected from F, Cl, CN and CF 3 .
  • R represents phenyl or pyridinyl; said ring being 4-
  • R represents phenyl or pyridinyl; said ring being 4-
  • R represents H.
  • 3 R represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 (e.g. one, two or three) heteroatoms independently selected from O 3 S and N; said ring being optionally substituted with at least one (e.g. one, two, three or four) substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), Q-CO alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), cyano, Cj-Cg alkoxy (e.g.
  • R represents a phenyl or pyridinyl ring substituted with at least one substituent (e.g. one, two or three substituents) independently selected from halogen, cyano, nitro, methyl, trifiuoromethyl and methylcarbonyl.
  • substituent e.g. one, two or three substituents
  • R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro and trifiuoromethyl.
  • R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine and trifiuoromethyl.
  • R represents a phenyl group substituted with a trifiuoromethyl substituent (preferably in the meta position). 3 In still another embodiment, R represents a phenyl group substituted in the meta position with Br 3 Cl, CF 3 or CN.
  • Ci-Cg alkyl e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl
  • at least one substituent e.g. one or two substituents
  • substituents independently selected from fluoro, hydroxyl and Cj-Cg alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n- pentoxy or n-hexoxy).
  • R represents hydrogen or Q-C4 alkyl optionally substituted with one or two substituents independently selected from hydroxyl and Q-C4 alkoxy.
  • R represents hydrogen
  • X represents a single bond or a group -Cj-Cg
  • alkylene being optionally further substituted by OH, halogen, CN, NR R , C1-C3
  • X represents a single bond or a group -Cj-Cg
  • alkylene-Y- wherein Y represents a single bond, oxygen atom, NR or S(0) w ; said alkylene being optionally further substituted by OH, halogen, CN, Cj-C 3
  • X represents a group -Ci-Cg alkylene-Y- and Y represents a single bond and the alkylene moiety is a linear or branched Ci-Cg or C1-C4 or C1-C2 alkylene, optionally substituted by OH, halogen, CN, CO2R or C1-C3 alkoxy.
  • X represents a group -Ci-Cg alkylene-Y- and Y represents a single bond and the alkylene moiety is a linear or branched C1-C6 or C1-C4 or C1-C2 alkylene, optionally substituted by OH, halogen, CN or C1-C3 alkoxy.
  • X represents unsubstituted C1-C2 alkylene, particularly methylene.
  • X represents a single bond.
  • R and X are joined together such that the group
  • 4 -NR X together represents a 5 to 7 membered azacyclic ring optionally incorporating one
  • Ci-Cg alkyl or NR R said alkyl being optionally further substituted by OH.
  • 44 hheetteerrooaattoomm sseelleecctteedd ffrroomm OO,, SS aanndd NR include pyrrolidine, piperidine, piperazine, morpholine and perhydroazepine.
  • R represents a monocyclic ring system selected from i) phenoxy, ii) phenyl, iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms) independently selected from nitrogen, oxygen and sulphur, iv) a saturated or partially unsaturated C 3 -Cg cycloalkyl ring, or v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms) independently
  • R represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)t or Ci-Cg alkylene optionally comprising one or more (e.g. one or two) internal or terminal heteroatoms selected from
  • oxygen, sulphur and NR being optionally substituted by at least one substituent (e.g. one or two substituents) independently selected from hydroxyl, oxo and Cj-Cg alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy); the monocyclic or bicyclic ring system being optionally substituted (on a ring atom) by at least one substituent (e.g. one, two or three substituents) independently selected from oxygen (e.g. to form an N-oxide), CN, OH, C1-C6 alkyl (e.g.
  • CJ-CO alkoxy e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy
  • CJ-CO alkoxy e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy
  • halogen e.g. fluorine, chlorine, bromine or iodine
  • NR R NO2, OSO2R , CO2R ,
  • Ci-Cg alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, Cj-Cg alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy), Cj-Cg alkyltbio (e.g. methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio,
  • R 22 tert-butylthio, n-pentylthio or n-hexylthio) and -C(O)NR R ; or R may also represent hydrogen.
  • Examples of a 5- or 6-membered heteroaromatic ring include furanyl, thienyl, pyrrolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyrimidinyl and pyrazinyl.
  • Preferred heteroaromatic rings include isoxazolyl, pyridinyl, imidazolyl and triazolyl.
  • a "saturated or partially unsaturated C3-C6 cycloalkyl ring” denotes a 3- to 6-membered non-aromatic cycloalkyl ring optionally incorporating one or more double bonds, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl.
  • a preferred cycloalkyl ring is cyclopropyl.
  • a "saturated or partially unsaturated 4- to 7-membered heterocyclic ring" as specified above denotes a 4- to 7-membered non-aromatic heterocyclic ring optionally incorporating one or more double bonds and optionally incorporating a carbonyl group, examples of which include tetrahydrofuranyl, tetramethylenesulfonyl, tetrahydropyranyl, 4-oxo-4H-pyranyl (4H-pyran-4-onyl), pyrrolidinyl, 3-pyrrolinyl, imidazolidinyl, 1,3-dioxolanyl (1,3-dioxacyclo ⁇ entanyl), piperidinyl, piperazinyl, morpholinyl, perhydroazepinyl (hexamethylene iminyl), pyrrolidonyl and piperidonyl.
  • a preferred saturated or partially unsaturated 4- to 7- membered heterocyclic ring is
  • bicyclic ring systems in which the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group
  • a linker group examples include biphenyl, thienylphenyl, pyrazolylphenyl, phenoxyphenyl, phenylcyclopropyl, naphthyl, indanyl, quinolyl, tetrahydroquinolyl, benzofuranyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, isoquinolyl, chromanyl, indenyl, quinazolyl, quinoxalyl, chromanyl, isocromanyl, 3H-indolyl, lH-indazolyl, quinuclidyl, tetrahydronaphth
  • R represents a substituted monocyclic ring system as defined above.
  • R represents a substituted bicyclic ring system as defined above.
  • R represents H
  • R represents a monocyclic ring system selected from i) phenoxy, ii) phenyl, iii) a 5- or 6-membered heteroaromatic ring comprising one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur, iv) a saturated or partially unsaturated C3-C6 cycloalkyl ring, or v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising one
  • R represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, methylene and S(O)t; the monocyclic or bicyclic ring system being substituted by one or two substituents
  • R represents a monocyclic ring system selected from phenyl or a 5- or 6-membered heteroaromatic ring comprising one or two ring heteroatoms independently selected from nitrogen and oxygen, the monocyclic ring system being substituted by one or two substituents independently selected from OH,
  • R represents phenyl or pyridinyl substituted
  • R represents phenyl substituted by one or
  • R represents H
  • R represents an unsubstituted C ⁇ -Cg cycloalkyl ring, particularly cyclopropyl.
  • x is 2.
  • p is 2.
  • R and R independently represent H, Ci -C3 alkyl or C2-C3 alkylcarbonyl.
  • R and R independently represent H, Cj -C3 alkyl or
  • R represents hydrogen, methyl, ethyl, methylcarbonyl (acetyl), ethylcarbonyl, methoxycarbonyl or ethoxycarbonyl.
  • v is 2.
  • R represents hydrogen, Cj-Cg alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C3-C8 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl); said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, C i -C 3 alkoxy and CONR 59 R 60 .
  • Cj-Cg alkyl e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or
  • R represents C1-C4 alkyl or C3-C6 cycloalkyl.
  • R represents C1-C3 alkyl (particularly methyl, ethyl or isopropyl) or cyclopropyl.
  • R represents C1-C3 alkyl (particularly methyl, ethyl or isopropyl) or cyclopropyl.
  • R 5S , R 59 , R 60 , R 62 , R 63 , R 64 , R 65 and R 66 each independently represent hydrogen or C1-C3 alkyl, particularly methyl, ethyl, 1 -propyl or 2-propyl.
  • I Tn an em Tb-odJi-men * t o*f * tih.e i-nven * ti•on, - Rn 15 , R r> 16 , rR, 17 , R r, 1 S , nR 1 * , rR, 30 , R ⁇ > 33 , r R, 34 , rR.35 , whatsoeverR36 , R _,37 , R 38 , R 47 , R 4S , R 61 , R 22 , R 23 , R 24 , R 26 . R 27 , R 31 , R 32 .
  • R 39 , R 40 , R 42 , R 43 , R 44 , R 45 , R 46 , R 49 , R 50 , R 51 , R 52 , R 53 , R 54 , R 55 , R 56 , R 57 , R 58 , R 59 , R 60 , R 62 , R 63 , R 64 , R 65 and R 66 each independently represent hydrogen or methyl.
  • R represents hydrogen
  • R represents methyl
  • 14 W represents a 5-membered heteroaromatic ring, and the group R and the 2- pyridone ring are bonded to the 5-membered ring W in a 1,2-relationship;
  • R represents phenyl or pyridinyl; said ring being optionally substituted with at least one substituent selected from F, Cl, CN and CF3;
  • R represents H
  • R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro or trifluoromethyl;
  • X represents unsubstituted Q-C2 alkylene, particularly methylene
  • R represents phenyl substituted by one or two substituents independently selected
  • R represents methyl
  • 14 W represents a 5-membered heteroaromatic ring, and the group R and the 2- pyridone ring are bonded to the 5-membered ring W in a 1,2-relationship;
  • R represents phenyl or pyridinyl; said ring being optionally substituted with at least one substituent selected from F 5 Cl, CN and CF3;
  • R represents H;
  • R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro or trifluoromethyl;
  • X represents unsubstituted C1-C2 alkylene, particularly methylene; and R represents H.
  • R represents methyl
  • 14 W represents a 5-membered heteroaromatic ring, and the group R and the 2- pyridone ring are bonded to the 5-membered ring W in a 1 ,2-relationship;
  • R represents phenyl or pyridinyl; said ring being 4- (para) substituted with F, Cl or
  • R represents H
  • R represents a phenyl group substituted in the meta position with Br 5 Cl, CF3 or CN;
  • X represents a linear or branched C1-C4 alkylene, optionally substituted by OH, halogen, CN, CO2R or C1-C3 alkoxy; and R represents H.
  • Examples of compounds of the invention include :
  • the present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which comprises,
  • R 14 14 with a nucleophile R -W-M wherein R and W are as defined in formula (I) and M represents an organo-tin or organo boronic acid group; or
  • the reaction may conveniently be carried out in an organic solvent such as dichloromethane or N-methylpyrrolidinone at a temperature, for example, in the range from 0 °C to the boiling point of the solvent.
  • a base and/or a coupling reagent such as HATU (O-(7-Azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate), HOAT (l-Hydroxy-7-azabenzotriazole), HOBT (1-Hydroxybenzotriazole hydrate) or DIEA (N,N-Diisopropylethylamine) may be added.
  • HATU O-(7-Azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate
  • HOAT l-Hydroxy-7-azabenzotriazo
  • the reaction may conveniently be carried out in an organic solvent such as DMF, NMP or toluene or a mixture thereof at elevated temperature (i.e. above ambient temperature, 20 0 C), for example, in the range from 50 0 C to 150 °C and in the presence of a suitable transition metal catalyst such as bis(tri-t-butylphosphine)palladium. If necessary or desired, a base such as potassium carbonate may be added.
  • an organic solvent such as DMF, NMP or toluene or a mixture thereof at elevated temperature (i.e. above ambient temperature, 20 0 C)
  • a suitable transition metal catalyst such as bis(tri-t-butylphosphine)palladium
  • a base such as potassium carbonate may be added.
  • reaction may conveniently be carried out by heating together the two starting materials in a suitable organic solvent such as acetonitrile at a temperature, for example, in the range from 50 0 C to 150 0 C.
  • a suitable organic solvent such as acetonitrile
  • the compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate
  • a pharmaceutically acceptable salt thereof preferably an acid addition salt such as a hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate
  • the compounds of formula (T) and their pharmaceutically acceptable salts have activity as pharmaceuticals, in particular as modulators of serine proteases such as proteinase 3 and pancreatic elastase and, especially, human neutrophil elastase, and may therefore be beneficial in the treatment or prophylaxis of inflammatory diseases and conditions.
  • the compounds of formula (I) and their pharmaceutically acceptable salts can be used in the treatment of diseases of the respiratory tract such as obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug- induced (including aspirin and NS AID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper- responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal
  • the compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of bone and joints such as arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection-related arthopathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal- induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis
  • vasculitides associated with viral infection hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; drug-induced arthalgias, tendonititides, and myopathies.
  • the compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of pain and connective tissue remodelling of musculoskeletal disorders due to injury [for example, sports injury] or disease: arthitides (for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy), other joint disease (such as intervertebral disc degeneration or temporomandibular joint degeneration), bone remodelling disease (such as osteoporosis, Paget's disease or osteonecrosis), polychondritits, scleroderma, mixed connective tissue disorder, spondyloarthropathies or periodontal disease (such as periodontitis).
  • arthitides for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy
  • other joint disease such as intervertebral disc degeneration or temporomandibular joint degeneration
  • bone remodelling disease such as osteoporosis, Paget's disease or osteon
  • the compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of skin such as psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both in
  • the compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the eye such as blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial.
  • diseases of the eye such as blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; ulceris; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial.
  • the compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the gastrointestinal tract such as glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, non-inflammatory diarrhoea, and food-related allergies which may have effects remote from the gut (for example, migraine, rhinitis or eczema).
  • diseases of the gastrointestinal tract such as glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, non-inflammatory diarrhoe
  • the compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the cardiovascular system such as atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis , inflammatory and autoimmune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.
  • diseases of the cardiovascular system such as atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis , inflammatory and autoimmune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infect
  • the compounds of formula (I) and their pharmaceutically acceptable salts can also be used in oncology such as in the treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes.
  • oncology such as in the treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes
  • the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis and gastric mucosal injury.
  • ARDS adult respiratory distress syndrome
  • cystic fibrosis pulmonary emphysema
  • bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension
  • asthma including refractive asthma
  • the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and rhinitis.
  • COPD chronic obstructive pulmonary disease
  • the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the present invention provides a compound of formula (I) or a pharmaceutically- acceptable salt thereof as hereinbefore defined for use in therapy.
  • the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.
  • the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of neutrophil elastase activity is beneficial.
  • the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in the treatment of an inflammatory disease or condition.
  • the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in treating adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury.
  • ARDS adult respiratory distress syndrome
  • cystic fibrosis pulmonary emphysema
  • bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive
  • the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly.
  • Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question.
  • Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
  • the invention also provides a method of treating, or reducing the risk of, a disease or condition in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
  • the invention still further provides a method of treating, or reducing the risk of, an inflammatory disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
  • the invention still further provides a method of treating, or reducing the risk of, adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
  • ARDS adult respiratory distress syndrome
  • cystic fibrosis pulmonary emphysema
  • bronchitis including chronic bronchit
  • the invention still further provides a method of treating, or reducing the risk of, chronic obstructive pulmonary disease (COPD) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
  • COPD chronic obstructive pulmonary disease
  • the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated.
  • the daily dosage of the compound of the invention may be in the range from 0.05 mg/kg to 100 mg/kg.
  • the compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • a pharmaceutically acceptable adjuvant diluent or carrier.
  • Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
  • the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • the invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.
  • compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler ® ; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of solutions or suspensions; or by subcutaneous administration; or by rectal administration in the form of suppositories; or transdermally.
  • HFA heptafluoroalkane
  • Dry powder formulations and pressurized HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation.
  • the compound is desirably finely divided.
  • the finely divided compound preferably has a mass median diameter of less than 10 ⁇ m, and may be suspended in a propellant mixture with the assistance of a dispersant, such as a C S -C 20 fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
  • a dispersant such as a C S -C 20 fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
  • the compounds of the invention may also be administered by means of a dry powder inhaler.
  • the inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.
  • a carrier substance for example, a mono-, di- or polysaccharide, a sugar alcohol, or another polyol.
  • Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch.
  • the finely divided compound may be coated by another substance.
  • the powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.
  • This spheronized powder may be filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler ® in which a dosing unit meters the desired dose which is then inhaled by the patient.
  • a multidose inhaler for example, that known as the Turbuhaler ® in which a dosing unit meters the desired dose which is then inhaled by the patient.
  • the active ingredient with or without a carrier substance, is delivered to the patient.
  • the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets.
  • an adjuvant or a carrier for example, lactose, saccharose, sorbitol, mannitol
  • a starch for example, potato starch, corn starch or amylopectin
  • a cellulose derivative for example, gelatine or polyvinylpyrrolidone
  • a lubricant for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax
  • the cores may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
  • a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide.
  • the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.
  • the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol.
  • Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets.
  • liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.
  • Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol.
  • Such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art.
  • the compounds of the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.
  • the invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed.
  • a compound of the invention or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention
  • another therapeutic agent or agents for the treatment of one or more of the conditions listed.
  • the compounds of the invention may be combined with agents listed below.
  • Non-steroidal anti-inflammatory agents including non-selective cyclo-oxygenase COX-I / COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin); selective COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib); cyclo-oxygenase inhibiting nitric oxide donors (CINODs); glucocorticosteroids (whether administered by topical, oral, intravepiroxicam, rt
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a cytokine or agonist or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma- interferons; insulin-like growth factor type I (IGF-I); interleukins (IL) including ILl to 23, and interleukin antagonists or inhibitors such as anakinra; tumour necrosis factor alpha (TNF- ⁇ ) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab, and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular-weight agents such as pentoxyfylline.
  • a cytokine or agonist or antagonist of cytokine function including agents which act on cytokine signal
  • Lymphocytes such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax 11-15).
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a modulator of chemokine receptor function such as an antagonist of CCRl, CCR2, CCR2A, CCR2B, CCR3, CCR4, o CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl,
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an inhibitor of matrix metalloprotease s (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-I), collagenase-2 (MMP-8), collagenase-3 (MMP- 13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-IO), and stromelysin-3 (MMP- 11) and MMP-9 and MMP- 12, including agents such as doxycycline.
  • MMPs matrix metalloprotease s
  • the present invention still further relates to the combination of a compound of the 0 invention, or a pharmaceutically acceptable salt thereof, and a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2-alkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a 5 pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2- cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a receptor antagonist for leukotrienes (LT) o B4, LTC4, LTD4, and LTE4.
  • a receptor antagonist for leukotrienes (LT) o B4, LTC4, LTD4, and LTE4 selected from the group consisting of the phenothiazin-3-ls such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.
  • PDE phosphodiesterase
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.
  • a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a proton pump inhibitor (such as omeprazole) or a gastroprotective histamine type 2 receptor antagonist.
  • a proton pump inhibitor such as omeprazole
  • a gastroprotective histamine type 2 receptor antagonist such as a gastroprotective histamine type 2 receptor antagonist.
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an antagonist of the histamine type 4 receptor.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.
  • an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochlor
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an anticholinergic agents including muscarinic receptor (Ml, M2, and M3) antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
  • Ml, M2, and M3 antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, or pirbuterol, or a chiral enantiomer thereof.
  • a beta-adrenoceptor agonist including beta receptor subtypes 1-4
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a chromone, such as sodium cromoglycate or nedocromil sodium.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.
  • a glucocorticoid such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an agent that modulates a nuclear hormone receptor such as PPARs.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and another systemic or topically-applied anti- inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
  • another systemic or topically-applied anti- inflammatory agent such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and combinations of aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.
  • aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine
  • immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse transcripta
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist; a lipid lowering agent such as a statin or a fibrate; a modulator of blood cell morphology such as pentoxyfylline; thrombolytic, or an anticoagulant such as a platelet aggregation inhibitor.
  • a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist
  • ACE angiotensin-converting enzyme
  • angiotensin-2 receptor antagonist angiotensin-2 receptor antagonist
  • a lipid lowering agent such as a statin or a fibrate
  • a modulator of blood cell morphology such as
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole, pramipexole, a MAOB inhibitor such as selegine and rasagiline, a comP inhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptake inhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist or an inhibitor of neuronal nitric oxide synthase), or an anti- Alzheimer's drug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor, propentofylline or metrifonate.
  • a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dop
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an agent for the treatment of acute or chronic pain, such as a centrally or peripherally-acting analgesic (for example an opioid or derivative thereof), carbamazepine, phenytoin, sodium valproate, amitryptiline or other anti-depressant agent-s, paracetamol, or a non-steroidal anti-inflammatory agent.
  • the present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof.
  • a compound of the present invention, or a pharmaceutically acceptable salt thereof can also be used in combination with an anti-osteoporosis agent including a hormonal agent such as raloxifene, or a biphosphonate such as alendronate.
  • the present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a: (i) tryptase inhibitor; (ii) platelet activating factor (PAF) antagonist; (iii) interleukin converting enzyme (ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitors including VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor such as an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, for example Gefitinib or Imatinib mesylate), a serine / threonine kinase (such as an inhibitor of
  • - or B.sub2. -receptor antagonist for example colchicine;
  • anti-gout agent for example colchicine;
  • xanthine oxidase inhibitor for example allopurinol;
  • uricosuric agent for example probenecid, sulfinpyrazone or benzbromarone;
  • growth hormone secretagogue for example transforming growth factor (TGF ⁇ );
  • PDGF platelet-derived growth factor
  • PDGF platelet-derived growth factor
  • fibroblast growth factor for example basic fibroblast growth factor (bFGF);
  • GM-CSF granulocyte macrophage colony stimulating factor
  • capsaicin cream for example tachykinin NK.
  • NKP-608C sub 1. or NK.sub3.
  • receptor antagonist such as NKP-608C, SB-233412 (talnetant) or D-4418;
  • elastase inhibitor such as UT-77 or ZD-0892;
  • TACE TNF-alpha converting enzyme inhibitor
  • iNOS induced nitric oxide synthase
  • chemoattractant receptor-homologous molecule expressed on TH2 cells such as a CRTH2 antagonist
  • inhibitor of P38 agent modulating the function of Toll-like receptors (TLR),
  • agent modulating the activity of purinergic receptors such as P2X7; or
  • inhibitor of transcription factor activation such as NFkB, API, or STATS.
  • a compound of the invention, or a pharmaceutically acceptable salt thereof can also be used in combination with an existing therapeutic agent for the treatment of cancer, for example suitable agents include:
  • an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as vincri
  • an agent which inhibits cancer cell invasion for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function
  • an inhibitor of growth factor function for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbbl antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3- morpholinopropoxy)quinazolin-4-amine (gefitinib, AZDl 839), N-(3-ethynylphenyl)-6,7-
  • a growth factor antibody for example
  • the compounds of the invention may be administered in conjunction with a second active ingredient which is selected from: a) a PDE4 inhibitor including an inhibitor of the isoform PDE4D; b) a ⁇ -adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol or indacaterol; c) a muscarinic receptor antagonist (for example a Ml , M2 or M3 antagonist, such as a selective M3 antagonist) such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine; d) a modulator of chemokine receptor function (such as a CCRl or CCR8 receptor antagonist); e) an inhibitor of chem
  • HATU O-(7-Azabenzotriazol-l-yl)-N,N,N',N f -tetramethyluronium hexafluorophosphate
  • TMP 2,2,6,6-Tetramethylpiperidine
  • the starting materials for the examples above are either commercially available or are readily prepared by standard methods from known materials. For example, the following reactions are illustrations, but not a limitation, of the preparation of some of the starting materials.
  • reaction mixture o was diluted with DCM, washed with aqueous NaHCO 3 , with aqueous NaS 2 O 4 and water, dried (Na 2 SO 4 ), and evaporated to give the title compound SMl (200 mg).
  • the assay uses Human Neutrophil Elastase (HNE) purified from serum (Calbiochem art.
  • HNE Human Neutrophil Elastase
  • HNE was stored in 5 50 mM sodium acetate (NaOAc), 200 mM sodium chloride (NaCl), pH 5.5 with added
  • protease substrate used was Elastase Substrate V Fluorogenic
  • MeOSuc- AAPV-AMC (Calbiochem art. 324740; Ref. Castillo, MJ. et al., 1979, Anal.
  • the substrate was stored in dimethyl sulphoxide (DMSO) at -20 0 C.
  • DMSO dimethyl sulphoxide
  • the assay additions were as follows: Test compounds and controls were added to black 96- 0 well flat-bottom plates (Greiner 655076), 1 ⁇ L in 100% DMSO, followed by 30 ⁇ L HNE in assay buffer with 0.01% Triton (trade mark) X-100 detergent.
  • the assay buffer constitution was: 100 mM Tris(hydroxymethyl)aminomethane (TRIS) (pH 7.5) and 500 mM NaCl.
  • the enzyme and the compounds were incubated at room temperature for 15 minutes. Then 30 ⁇ l substrate in assay buffer was added. The assay was incubated for 30 minutes at room temperature.
  • the concentrations of HNE enzyme and substrate during the incubation were 1.7 nM and 100 ⁇ M, respectively.
  • the assay was then stopped by adding 60 ⁇ l stop solution (140 mM acetic acid, 200 mM sodium monochloroacetate, 60 mM sodium acetate, pH 4.3). Fluorescence was measured on a Wallac 1420 Victor 2 instrument at settings: Excitation 380 nm, Emission 460 nm. IC50 values were determined using Xlfit curve fitting using model 205.

Abstract

The invention provides compounds of formula (1) wherein R1, R3, R4, R5, R6, R14, X and W are as defined in the specification and optical isomers, racemates and tautomers thereof, and pharmaceutically acceptable salts thereof; together with processes for their preparation, pharmaceutical compositions containing them and their use in therapy. The compounds are inhibitors of human neutrophil elastase.

Description

A system for wireless transmission of measurement results intended to be used in a coupling device and a use of the system in a vehicle.
Field of the Invention
The present invention relates to 2-pyridone derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
Background of the Invention
Elastases are possibly the most destructive enzymes in the body, having the ability to degrade virtually all connective tissue components. The uncontrolled proteolytic degradation by elastases has been implicated in a number of pathological conditions. Human neutrophil elastase (hNE), a member of the chymotrypsin superfamily of serine proteases is a 33-KDa enzyme stored in the azurophilic granules of the neutrophils. In neutrophils the concentration of NE exceeded 5 mM and its total cellular amount has been estimated to be up to 3 pg. Upon activation, NE is rapidly released from the granules into the extracellular space with some portion remaining bound to neutrophil plasma membrane (See Kawabat et al. 2002, Eur. J. Pharmacol. 451, 1-10). The main intracellular physiological function of NE is degradation of foreign organic molecules phagocytosed by neutrophils, whereas the main target for extracellular elastase is elastin (Janoff and Scherer, 1968, J. Exp. Med. 128, 1137-1155). NE is unique, as compared to other proteases (for example, proteinase 3) in that it has the ability to degrade almost all extracellular matrix and key plasma proteins (See Kawabat et al., 2002, Eur. J. Pharmacol. 451, 1-10). It degrades a wide range of extracellular matrix proteins such as elastin, Type 3 and type 4 collagens, laminin, fibronectin, cytokines, etc. (Ohbayashi, H., 2002, Expert Opin. Investig. Drugs, 11, 965-980). NE is a major common mediator of many pathological changes seen in chronic lung disease including epithelial damage (Stockley, R. A. 1994, Am. J. Resp. Crit. Care Med. 150, 109-113).
The destructive role of NE was solidified almost 40 years ago when Laurell and Eriksson reported an association of chronic airflow obstruction and emphysema with deficiency of serum ^-antitrypsin (Laurell and Eriksson, 1963, Scand. J. Clin. Invest. 15, 132-140). Subsequently it was determined that a\ -antitrypsin is the most important endogenous inhibitor of human NE. The imbalance between human NE and endogenous antiprotease is believed to cause excess human NE in pulmonary tissues which is considered as a major pathogenic factor in chronic obstructive pulmonary disease (COPD). The excessive human NE shows a prominent destructive profile and actively takes part in destroying the normal pulmonary structures, followed by the irreversible enlargement of the respiratory airspaces, as seen mainly in emphysema. There is an increase in neutrophil recruitment into the lungs which is associated with increased lung elastase burden and emphysema in ^-proteinase inhibitor-deficient mice (Cavarra et al, 1996, Lab. Invest. 75, 273-280). Individuals with higher levels of the NE-OC1 protease inhibitor complex in bronchoalveolar lavage fluid show significantly accelerated decline in lung functions compared to those with lower levels (Betsuyaku et al. 2000, Respiration, 67, 261-267). Instillation of human NE via the trachea in rats causes lung haemorrhage, neutrophil accumulation during acute phase and emphysematous changes during chronic phase (Karaki et al., 2002, Am. J. Resp. Crit Care Med., 166, 496-500). Studies have shown that the acute phase of pulmonary emphysema and pulmonary haemorrhage caused by NE in hamsters can be inhibited by pre-treatment with inhibitors of NE ( Fujie et al.,1999, Inflamm. Res. 48, 160-167).
Neutrophil-predominant airway inflammation and mucus obstruction of the airways are major pathologic features of COPD, including cystic fibrosis and chronic bronchitis. NE impairs mucin production, leading to mucus obstruction of the airways. NE is reported to increase the expression of major respiratory mucin gene, MUC5AC (Fischer, B.M & Voynow, 2002, Am. J. Respir. Cell Biol., 26, 447-452). Aerosol administration of NE to guinea pigs produces extensive epithelial damage within 20 minutes of contact (Suzuki et al., 1996, Am. J. Resp. Crit. Care Med., 153, 1405-1411). Furthermore NE reduces the ciliary beat frequency of human respiratory epithelium in vitro (Smallman et al., 1984, Thorax, 39, 663-667) which is consistent with the reduced mucociliary clearance that is seen in COPD patients (Currie et al., 1984, Thorax, 42, 126-130). The instillation of NE into the airways leads to mucus gland hyperplasia in hamsters (Lucey et al., 1985, Am. Resp. Crit. Care Med., 132, 362-366). A role for NE is also implicated in mucus hypersecretion in asthma. In an allergen sensitised guinea pig acute asthma model an inhibitor of NE prevented goblet cell degranulation and mucus hypersecretion (Nadel et al., 1999, Eur. Resp. J., 13, 190-196). NE has been also shown to play a role in the pathogenesis of pulmonary fibrosis. NE: cti-protenase inhibitor complex is increased in serum of patients with pulmonary fibrosis, which correlates with the clinical parameters in these patients (Yamanouchi et al., 1998, Eur. Resp. J. 11, 120-125). In a murine model of human pulmonary fibrosis, a NE s inhibitor reduced bleomycin-induced pulmonary fibrosis (Taooka et al., 1997, Am. J. Resp. Crit. Care Med., 156, 260-265). Furthermore investigators have shown that NE deficient mice are resistant to bleomycin-induced pulmonary fibrosis (Dunsmore et al., 2001, Chest, 120, 35S-36S). Plasma NE level was found to be elevated in patients who progressed to ARDS implicating the importance of NE in early ARDS disease pathogenesis. (Donnelly Q et al., 1995, Am. J. Res. Crit. Care Med., 151, 428-1433). The antiproteases and NE complexed with antiprotease are increased in lung cancer area (Marchandise et al., 1989, Eur. Resp. J. 2, 623-629). Recent studies have shown that polymorphism in the promoter region of the NE gene are associated with lung cancer development (Taniguchi et al., 2002, Clin. Cancer Res., 8, 1115-1120. 5
Acute lung injury caused by endotoxin in experimental animals is associated with elevated levels of NE ( Kawabata, et al., 1999, Am. J. Resp. Crit. Care, 161, 2013-2018). Acute lung inflammation caused by intratracheal injection of lipopoly saccharide in mice has been shown to elevate the NE activity in bronchoalveolar lavage fluid which is significantly 0 inhibited by a NE inhibitor (Fujie et al., 1999, Eur. J. Pharmacol, 374, 117-125; Yasui, et al., 1995, Eur. Resp. J., 8, 1293-1299). NE also plays an important role in the neutrophil- induced increase of pulmonary microvascular permeability observed in a model of acute lung injury caused by tumour necrosis factor α (TNFα) and phorbol myristate acetate (PMA) in isolated perfused rabbit lungs (Miyazaki et al., 1998, Am. J. Respir. Crit. Care 5 Med., 157, 89-94).
A role for NE has also been suggested in monocrotoline-induced pulmonary vascular wall thickening and cardiac hypertrophy (Molteni et al., 1989, Biochemical Pharmacol. 38, 2411-2419). Serine elastase inhibitor reverses the monocrotaline-induced pulmonary o hypertension and remodelling in rat pulmonary arteries (Cowan et al., 2000, Nature Medicine, 6, 698-702). Recent studies have shown that serine elastase, that is, NE or vascular elastase are important in cigarette smoke-induced muscularisation of small pulmonary arteries in guinea pigs (Wright et al., 2002, Am. J. Respir. Crit. Care Med., 166, 954-960).
NE plays a key role in experimental cerebral ischemic damage (Shimakura et al., 2000, Brain Research, 858, 55-60), ischemia-reperfusion lung injury (Kishima et al., 1998, Ann. Thorac. Surg. 65, 913-918) and myocardial ischemia in rat heart (Tiefenbacher et al., 1997, Eur. J. Physiol., 433, 563-570). Human NE levels in plasma are significantly increased above normal in inflammatory bowel diseases, for example, Crohn's disease and ulcerative colitis (Adeyemi et al., 1985, Gut, 26, 1306-1311). In addition NE has also been assumed to be involved in the pathogenesis of rheumatoid arthritis (Adeyemi et al., 1986, Rheumatol. Int., 6, 57). The development of collagen induced arthritis in mice is suppressed by a NE inhibitor (Kakimoto et al., 1995, Cellular Immunol. 165, 26-32).
Thus, human NE is known as one of the most destructive serine proteases and has been implicated in a variety of inflammatory diseases. The important endogenous inhibitor of human NE is Ot1 -antitrypsin. The imbalance between human NE and antiprotease is believed to give rise to an excess of human NE resulting in uncontrolled tissue destruction. The protease/ antiprotease balance may be upset by a decreased availability of αrantitrypsin either through inactivation by oxidants such as cigarette smoke, or as a result of genetic inability to produce sufficient serum levels. Human NE has been implicated in the promotion or exacerbation of a number of diseases such as pulmonary emphysema, pulmonary fibrosis, adult respiratory distress syndrome (ARDS), ischemia reperfusion injury, rheumatoid arthritis and pulmonary hypertension.
Disclosure of the Invention
In accordance with the present invention, there is therefore provided a compound of formula (I)
Figure imgf000006_0001
(I)
wherein
R represents hydrogen or Cj-Cg alkyl;
W represents a 5-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group; and wherein the heterocyclic ring is optionally substituted by at least one substituent selected from halogen, Cj-C4 alkyl, Cj- C4 alkoxy, CN, OH, NO2, C1-C3 alkyl substituted by one or more F atoms, C1-C3 alkoxy substituted by one or more F atoms, NR10R1 \ C≡CR15, CONR16R17, CHO, C2-C4 alkanoyl, S(O)xR18 and OSO2R19;
14
R represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; said ring being optionally substituted with at least one substituent selected from halogen, Cj-C4 alkyl, Cj-C4 alkoxy, CN, OH, NO2, C1-C3 alkyl substituted by one
12 13 30 or more F atoms, Cj -C3 alkoxy substituted by one or more F atoms, NR R , C≡CR ,
31 32 3^ 34
CONR R , CHO, C2-C4 alkanoyl, S(O)pR and OSO2R ;
R , R , R and R independently represent H5 CJ-CO alkyl, formyl or C2-CO alkanoyl; or the group -NR R or -NR R together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O5 S and NR26;
R and R independently represent H, C1-C3 alkyl or Si(CH3^;
R , R , R and R independently represent H or C1-C3 alkyl; said allcyl being optionally substituted by one or more F atoms;
R represents H or F;
R represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said ring being optionally substituted with at least one substituent selected from halogen, Ci-Cg alkyl, cyano, Ci-Cg alkoxy, nitro, methylcarbonyl, NR R , C1-C3 alkyl substituted by one or more F atoms or C1-C3 alkoxy substituted by one or more F atoms;
R and R independently represent H or C1-C3 alkyl; said alkyl being optionally further substituted by one or more F atoms;
4 R represents hydrogen or Ci-Cg alkyl optionally substituted with at least one substituent selected from fluoro, hydroxyl and Ci-Cg alkoxy;
24 X represents a single bond, O5 NR or a group -Ci-Cg alkylene-Y-, wherein Y
24 represents a single bond, oxygen atom, NR or S(0)w; and said alkylene being optionally further substituted by OH, halogen, CN5 NR37R38, Ci-C3 alkoxy, CONR39R40, CO2R66,
41 AO AI.
SO2R and SO2NR R ; 4 4 or R and X are joined together such that the group -NR X together represents a 5 to
7 membered azacyclic ring optionally incorporating one further heteroatom selected from
4 444 45 46 O O,, SS aanndd NNRR ;; ssaaiidd rriinngg bbeeiinngg ooppttiioonnaallllyy ssuubbssttiittiuted by C \-Cβ alkyl or NR R ; said alkyl being optionally further substituted by OH;
either R represents a monocyclic ring system selected from i) phenoxy, ii) phenyl, iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, iv) a saturated or partially unsaturated C3-C6 cycloalkyl ring, or v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at
20 least one ring heteroatom selected from oxygen, S(O)1- and NR , wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group,
or R represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)t or Cj-Cg alkylene optionally comprising one or more internal or terminal heteroatoms selected from oxygen, sulphur
27 and NR and being optionally substituted by at least one substituent selected from hydroxyl, oxo and C^-Cg alkoxy,
the monocyclic or bicyclic ring system being optionally substituted by at least one
47 48 substituent selected from oxygen, CN, OH, Ci -CO alkyl, C \ -Cg alkoxy, halogen, NR R ,
NO2, OSO2R49, CO2R50, C(=NH)NH2, C(O)NR51R52, C(S)NR53R54, SC(=NH)NH2,
NR55C(^NH)NH2, S(O)VR21, SO2NR56R57, C1-C3 alkoxy substituted by one or more F
58 atoms and C1-C3 alkyl substituted by SO2R or by one or more F atoms; said Ci-Cβ alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, Ci-C6 alkoxy, Ci-C6 alkylthio and -C(O)NR22R23;
or R may also represent H;
20
R represents hydrogen, Ci-C6 alkyl, Ci-C6 alkylcarbonyl or
Cj-C6 alkoxycarbonyl;
R represents hydrogen, Ci-C6 alkyl or C3-Cg cycloalkyl; said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, Ci-C3 alkoxy and CONR59R60;
^ 7 -IjQ
R and R independently represent H, Ci-C6 alkyl, formyl or C2-C6 alkanoyl;
R and R independently represent H, Ci-C6 alkyl, formyl, C2-C6 alkanoyl,
S(O)qR or SO2NR R ; said alkyl group being optionally further substituted by
64 65 halogen, CN, Ci -C4 alkoxy or CONR R ;
R and R independently represent H, Ci-C6 alkyl or C3-C6 cycloalkyl;
p is 0, 1 or 2; q is 0, 1 or 2; r is 0, 1 or 2; t is O5 1 or 2; w is 0, 1 or 2; x is 0, 1 or 2; v is 0, 1 or 2; R16, R17, R22, R23, R24, R26, R27, R31, R32, R39, R40, R42, R43, R44, R4S, R46, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R62, R63, R64, R65 and R66 each independently represent hydrogen or Cj-Cg alkyl;
or a pharmaceutically acceptable salt thereof.
In the context of the present specification, unless otherwise stated, an alkyl, alkenyl or alkynyl substituent group or an alkyl moiety in a substituent group may be linear or branched. Similarly, an alkylene group may be linear or branched.
In the definition of W, the 5-membered heterocyclic ring system may have alicyclic or aromatic properties and may thus be a saturated ring system or a partially unsaturated ring system or a fully unsaturated ring system.
R represents hydrogen or Cj-Cg alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl).
In one embodiment of the invention, R represents a C1-C4 or C1-C2 alkyl group, in particular a methyl group.
W represents a 5-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group; and wherein the heterocyclic ring is optionally substituted by at least one substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), C1-C4 alkyl (e.g. methyl, ethyl, n- propyl, isopropyl, n-butyl, isobutyl or tert-butyl), C1-C4 alkoxy (e.g. methoxy, ethoxy, n- propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy), cyano, OH, NO2, C1-C3 alkyl substituted by one or more F atoms (e.g. CH2F, CHF2, CF3, CH2CH2F, CH2CF3, CF2CF3, CH(CF3 )2 and CH2CH2CF3), C1-C3 alkoxy substituted by one or more F atoms (e.g. OCH2F, OCHF2, OCF3, OCH2CH2F, OCH2CF3, OCF2CF3, OCH(CF3)2 and OCH2CH2CF3), NR10R11, C=CR15 -C(O)NR16R17, CHO, C2-C4 alkanoyl (e.g. methylcarbonyl (acetyl), ethylcarbonyl, n-propylcarbonyl or isopropylcarbonyl), -S(O)xR18, and OSO2R19.
14 In one embodiment, the group R and the 2-pyridone ring are bonded to the 5-membered ring W in a 1,2-relationship.
In one embodiment, W represents a 5-membered heteroaromatic ring, especially an unsubstituted 5-membered heteroaromatic ring.
Examples of 5-membered heterocyclic ring systems that may be used, which may be saturated or partially unsaturated or fully unsaturated include any one of pyrrolidinyl, tetrahydrofuranyl, pyrroline, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, pyrrolidinonyl, imidazolidinonyl, oxazolyl, pyrazolyl, thiazolidinyl, thienyl, isoxazolyl, isothiazolyl, thiadiazolyl, pyrrolyl, furanyl, thiazolyl, imidazolyl, furazanyl, triazolyl and tetrazolyl.
Preferred ring systems for group W include pyrazolyl, thiazolyl, oxazolyl and imidazolyl.
In one embodiment, W represents pyrazolyl, triazolyl, thiazolyl, oxazolyl or imidazolyl.
14 R represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 (e.g. one, two or three) ring nitrogen atoms; said ring being optionally substituted with at least one (e.g. one, two, three or four) substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), C1-C4 alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl or tert-butyl), C1-C4 alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy), CN, OH, NO2, Cj -C3 alkyl substituted by one or more F atoms (e.g. CH2F, CHF2, CF3, CH2CH2F, CH2CF3, CF2CF3, CH(CF3)2 and CH2CH2CF3), Cr C3 alkoxy substituted by one or more F atoms (e.g. OCH2F, OCHF2, OCF3, OCH2CH2F, n 15 -in
OCH2CF3, OCF2CF3, OCH(CF3)2 and OCH2CH2CF3), NR. R 3 C≡CR ,
31 32 CONR R , CHO3 C2-C4 alkanoyl (e.g. methylcarbonyl (acetyl), ethylcarbonyl, n-
33 34 propylcarbonyl or isopropylcarbonyl), S(O)pR and OSO2R .
Examples of a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms include pyridinyl, pyrimidinyl, pyridazinyl, pyrazinyl and triazinyl. A preferred ring system is pyridinyl.
14 In one embodiment, one substituent on the aromatic ring of group R should be in the
4- (para) position relative to group W.
14 In one embodiment of the invention, R represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; said ring being optionally substituted with at least one substituent selected from F, Cl, CN and CF3.
14 In an embodiment of the invention, R represents phenyl or pyridinyl; said ring being optionally substituted with at least one substituent selected from F, Cl, CN and CF3.
14 In an embodiment of the invention, R represents a phenyl or pyridinyl group optionally substituted with one or two substituents independently selected from F, Cl, CN and CF3.
14 In an embodiment of the invention, R represents phenyl or pyridinyl; said ring being 4-
(para) substituted with F, Cl or CN and optionally further substituted.
14 In an embodiment of the invention, R represents phenyl or pyridinyl; said ring being 4-
(para) substituted with F, Cl or CN. In one embodiment, R represents H.
3 R represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 (e.g. one, two or three) heteroatoms independently selected from O3 S and N; said ring being optionally substituted with at least one (e.g. one, two, three or four) substituent selected from halogen (e.g. fluorine, chlorine, bromine or iodine), Q-CO alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), cyano, Cj-Cg alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy), nitro, methylcarbonyl, NR R , Cj -C3 alkyl substituted by one or more F atoms (e.g. CH2F, CHF2, CF3, CH2CH2F3 CH2CF3, CF2CF3, CH(CF3)2 and
CH2CH2CF3) and C1-C3 alkoxy substituted by one or more F atoms (e.g. OCH2F, OCHF2, OCF3, OCH2CH2F, OCH2CF3, OCF2CF3, OCH(CF3)2 and OCH2CH2CF3).
In one embodiment, R represents a phenyl or pyridinyl ring substituted with at least one substituent (e.g. one, two or three substituents) independently selected from halogen, cyano, nitro, methyl, trifiuoromethyl and methylcarbonyl.
3 In one embodiment, R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro and trifiuoromethyl.
3 In another embodiment, R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine and trifiuoromethyl.
In still another embodiment, R represents a phenyl group substituted with a trifiuoromethyl substituent (preferably in the meta position). 3 In still another embodiment, R represents a phenyl group substituted in the meta position with Br3 Cl, CF3 or CN.
4 R represents hydrogen or Ci-Cg alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) optionally substituted with at least one substituent (e.g. one or two substituents) independently selected from fluoro, hydroxyl and Cj-Cg alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n- pentoxy or n-hexoxy).
4 In one embodiment, R represents hydrogen or Q-C4 alkyl optionally substituted with one or two substituents independently selected from hydroxyl and Q-C4 alkoxy.
4 In another embodiment, R represents hydrogen.
In one embodiment of the invention, X represents a single bond or a group -Cj-Cg
24 alkylene-Y-, wherein Y represents a single bond, oxygen atom, NR or S(O)W; said
37 38 alkylene being optionally further substituted by OH, halogen, CN, NR R , C1-C3
3Q 40 66 41 AO 43 alkoxy, CONR R , CO2R , SO2R and SO2NR R
In one embodiment of the invention, X represents a single bond or a group -Cj-Cg
24 alkylene-Y-, wherein Y represents a single bond, oxygen atom, NR or S(0)w; said alkylene being optionally further substituted by OH, halogen, CN,
Figure imgf000014_0001
Cj-C3
39 40 41 42 43 alkoxy, CONR R , SO2R and SO2NR R . In an embodiment of the invention, X represents a group -Ci-Cg alkylene-Y- and Y represents a single bond and the alkylene moiety is a linear or branched Ci-Cg or C1-C4 or C1-C2 alkylene, optionally substituted by OH, halogen, CN, CO2R or C1-C3 alkoxy.
In an embodiment of the invention, X represents a group -Ci-Cg alkylene-Y- and Y represents a single bond and the alkylene moiety is a linear or branched C1-C6 or C1-C4 or C1-C2 alkylene, optionally substituted by OH, halogen, CN or C1-C3 alkoxy.
In another embodiment of the invention, X represents unsubstituted C1-C2 alkylene, particularly methylene.
In another embodiment of the invention, X represents a single bond.
4 In one embodiment of the invention, R and X are joined together such that the group
4 -NR X together represents a 5 to 7 membered azacyclic ring optionally incorporating one
44 further heteroatom selected from O, S and NR ; said ring being optionally substituted by
45 46 Ci-Cg alkyl or NR R ; said alkyl being optionally further substituted by OH.
Examples of a 5 to 7 membered azacyclic ring optionally incorporating one further
44 hheetteerrooaattoomm sseelleecctteedd ffrroomm OO,, SS aanndd NR include pyrrolidine, piperidine, piperazine, morpholine and perhydroazepine.
R represents a monocyclic ring system selected from i) phenoxy, ii) phenyl, iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms) independently selected from nitrogen, oxygen and sulphur, iv) a saturated or partially unsaturated C3-Cg cycloalkyl ring, or v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at least one ring heteroatom (e.g. one, two, three or four ring heteroatoms) independently
20 selected from oxygen, S(O)r and NR , wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group, or R represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)t or Ci-Cg alkylene optionally comprising one or more (e.g. one or two) internal or terminal heteroatoms selected from
27 oxygen, sulphur and NR and being optionally substituted by at least one substituent (e.g. one or two substituents) independently selected from hydroxyl, oxo and Cj-Cg alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy); the monocyclic or bicyclic ring system being optionally substituted (on a ring atom) by at least one substituent (e.g. one, two or three substituents) independently selected from oxygen (e.g. to form an N-oxide), CN, OH, C1-C6 alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl), CJ-CO alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy),
47 48 49 50 halogen (e.g. fluorine, chlorine, bromine or iodine), NR R , NO2, OSO2R , CO2R ,
C(=NH)NH2, C(O)NR51R52, C(S)NR53R54, SC(=NH)NH2, NR55C(=NH)NH2, -S(O)VR , SO2NR R , C1-C3 alkoxy substituted by one or more F atoms (e.g. OCH2F, OCHF2, OCF3, OCH2CH2F, OCH2CF3, OCF2CF3, OCH(CF3)2 and OCH2CH2CF3) and Ci-C3 alkyl substituted by SO2R or by one or more F atoms (e.g. CH2SO2R ,
CO CQ CH2CH2SO2R , CH(SO2R )CH3, CH2F, CHF2, CF3, CH2CH2F, CH2CF3, CF2CF3, CH(CF3)2 and CH2CH2CF3); said Ci-Cg alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, Cj-Cg alkoxy (e.g. methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, n-pentoxy or n-hexoxy), Cj-Cg alkyltbio (e.g. methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio,
22 23 tert-butylthio, n-pentylthio or n-hexylthio) and -C(O)NR R ; or R may also represent hydrogen.
Examples of a 5- or 6-membered heteroaromatic ring include furanyl, thienyl, pyrrolyl, oxazolyl, 1,2,4-oxadiazolyl, 1,3,4-oxadiazolyl, isoxazolyl, imidazolyl, pyrazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl, pyrimidinyl and pyrazinyl. Preferred heteroaromatic rings include isoxazolyl, pyridinyl, imidazolyl and triazolyl.
Unless otherwise indicated, a "saturated or partially unsaturated C3-C6 cycloalkyl ring" denotes a 3- to 6-membered non-aromatic cycloalkyl ring optionally incorporating one or more double bonds, examples of which include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclopentenyl and cyclohexenyl. A preferred cycloalkyl ring is cyclopropyl.
Unless otherwise indicated, a "saturated or partially unsaturated 4- to 7-membered heterocyclic ring" as specified above denotes a 4- to 7-membered non-aromatic heterocyclic ring optionally incorporating one or more double bonds and optionally incorporating a carbonyl group, examples of which include tetrahydrofuranyl, tetramethylenesulfonyl, tetrahydropyranyl, 4-oxo-4H-pyranyl (4H-pyran-4-onyl), pyrrolidinyl, 3-pyrrolinyl, imidazolidinyl, 1,3-dioxolanyl (1,3-dioxacycloρentanyl), piperidinyl, piperazinyl, morpholinyl, perhydroazepinyl (hexamethylene iminyl), pyrrolidonyl and piperidonyl. A preferred saturated or partially unsaturated 4- to 7- membered heterocyclic ring is pyrrolidonyl.
Examples of bicyclic ring systems in which the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group include biphenyl, thienylphenyl, pyrazolylphenyl, phenoxyphenyl, phenylcyclopropyl, naphthyl, indanyl, quinolyl, tetrahydroquinolyl, benzofuranyl, indolyl, isoindolyl, indolinyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzthiazolyl, purinyl, isoquinolyl, chromanyl, indenyl, quinazolyl, quinoxalyl, chromanyl, isocromanyl, 3H-indolyl, lH-indazolyl, quinuclidyl, tetrahydronaphthyl, dihydrobenzofuranyl, morpholine-4-ylphenyl, 1,3-benzodioxolyl, 2,3-dihydro-l,4- benzodioxinyl, 1,3-benzodioxinyl and 3,4-dihydro-isochromenyl.
In an embodiment of the invention, R represents a substituted monocyclic ring system as defined above.
In another embodiment of the invention, R represents a substituted bicyclic ring system as defined above.
In another embodiment of the invention, R represents H.
In a further embodiment of the invention, R represents a monocyclic ring system selected from i) phenoxy, ii) phenyl, iii) a 5- or 6-membered heteroaromatic ring comprising one or two ring heteroatoms independently selected from nitrogen, oxygen and sulphur, iv) a saturated or partially unsaturated C3-C6 cycloalkyl ring, or v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising one
20 or two ring heteroatoms independently selected from oxygen, S(O)r and NR , wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group; or R represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, methylene and S(O)t; the monocyclic or bicyclic ring system being substituted by one or two substituents
21 independently selected from OH, -S(O)VR and C1-C4 alkyl. In a still further embodiment of the invention, R represents a monocyclic ring system selected from phenyl or a 5- or 6-membered heteroaromatic ring comprising one or two ring heteroatoms independently selected from nitrogen and oxygen, the monocyclic ring system being substituted by one or two substituents independently selected from OH,
-S(O)VR21 and Ci-C4 alkyl.
In a still further embodiment of the invention, R represents phenyl or pyridinyl substituted
21 by -S(O)VR wherein v represents the integer 2.
In a still further embodiment of the invention, R represents phenyl substituted by one or
91 two substituents independently selected from OH, -S(O)VR~ and Ci -C4 alkyl.
In a still further embodiment of the invention, R represents H.
In a still further embodiment of the invention, R represents an unsubstituted Cβ-Cg cycloalkyl ring, particularly cyclopropyl.
In one embodiment, x is 2.
In one embodiment, p is 2.
In one embodiment, R and R independently represent H, Ci -C3 alkyl or C2-C3 alkylcarbonyl.
12 13
In one embodiment, R and R independently represent H, Cj -C3 alkyl or
C2-C3 alkylcarbonyl. 20 In a further embodiment, R represents hydrogen, methyl, ethyl, methylcarbonyl (acetyl), ethylcarbonyl, methoxycarbonyl or ethoxycarbonyl.
In one embodiment, v is 2.
21 R represents hydrogen, Cj-Cg alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-pentyl or n-hexyl) or C3-C8 cycloalkyl (cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl); said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH, CN, C i -C3 alkoxy and CONR59R60.
21 In an embodiment according to the invention, R represents C1-C4 alkyl or C3-C6 cycloalkyl.
21 In another embodiment, R represents C1-C3 alkyl (particularly methyl, ethyl or isopropyl) or cyclopropyl.
41 In another embodiment, R represents C1-C3 alkyl (particularly methyl, ethyl or isopropyl) or cyclopropyl.
In an embodiment of the invention, R15, R16, R17, R18, R19, R3°, R33, R34, R35, R36, R37,
J RtV38 , J RtV47 , J RΛ.48 , J RtV61 , J RtV22 , J RtV23 , J RtV24 , J RtV26 , J RK.27 , J RtV31 , RJtV32 , J RtV39 , J RtV4° j J RΛ.42 , RJtV43 , RJtV44 , RtV45 , RJX.46 ,
R49, R50, R51, R52, R53, R54, R55, R56, R57. R5S, R59, R60, R62, R63, R64, R65 and R66 each independently represent hydrogen or C1-C3 alkyl, particularly methyl, ethyl, 1 -propyl or 2-propyl.
I Tn an em Tb-odJi-men *t o*f* tih.e i-nven *ti•on, - Rn 15 , R r> 16 , rR, 17 , R r, 1 S , nR1* , rR,30 , R τ> 33 , r R,34 , rR.35 , „R36 , R _,37 , R38, R47, R4S, R61, R22, R23, R24, R26. R27, R31, R32. R39, R40, R42, R43, R44, R45, R46, R49, R50, R51, R52, R53, R54, R55, R56, R57, R58, R59, R60, R62, R63, R64, R65 and R66 each independently represent hydrogen or methyl.
In an embodiment of the invention, R represents hydrogen.
In an embodiment of the invention,
R represents methyl;
14 W represents a 5-membered heteroaromatic ring, and the group R and the 2- pyridone ring are bonded to the 5-membered ring W in a 1,2-relationship;
14 R represents phenyl or pyridinyl; said ring being optionally substituted with at least one substituent selected from F, Cl, CN and CF3;
R represents H;
3
R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro or trifluoromethyl;
4 R represents hydrogen;
X represents unsubstituted Q-C2 alkylene, particularly methylene; and
R represents phenyl substituted by one or two substituents independently selected
21 from OH, -S(O)VR and C 1-C4 alkyl wherein v represents the integer 2.
In an embodiment of the invention,
R represents methyl;
14 W represents a 5-membered heteroaromatic ring, and the group R and the 2- pyridone ring are bonded to the 5-membered ring W in a 1,2-relationship;
14
R represents phenyl or pyridinyl; said ring being optionally substituted with at least one substituent selected from F5 Cl, CN and CF3; R represents H; R represents a phenyl group substituted with one or two substituents independently selected from fluorine, chlorine, cyano, nitro or trifluoromethyl;
4 R represents hydrogen;
X represents unsubstituted C1-C2 alkylene, particularly methylene; and R represents H.
In an embodiment of the invention,
R represents methyl;
14 W represents a 5-membered heteroaromatic ring, and the group R and the 2- pyridone ring are bonded to the 5-membered ring W in a 1 ,2-relationship;
14
R represents phenyl or pyridinyl; said ring being 4- (para) substituted with F, Cl or
CN;
R represents H;
3 R represents a phenyl group substituted in the meta position with Br5 Cl, CF3 or CN;
4 R represents hydrogen;
X represents a linear or branched C1-C4 alkylene, optionally substituted by OH, halogen, CN, CO2R or C1-C3 alkoxy; and R represents H.
Examples of compounds of the invention include :
5-[l -(4-cyanophenyl)-lH-pyrazol-5-yl]-7V,6-dimethyl-2-oxo- 1 -[3-(trifluoromethyl)phenyl]-
1 ,2-dihydropyridine-3-carboxamide;
5-[l-(4-cyanophenyl)-lH-pyrazol-5-yl]-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-l-
[3-(trifiuoromethyl)phenyl]-l,2-dihydropyridine-3-carboxamide; 5-[2-amino-5-(4-chlorophenyl)-l,3-thiazol-4-yl]-iV,6-dimethyl-2-oxo-l-[3-
(trifluoromethyl)phenyl]- 152-dihydropyridine-3-carboxamide;
5-[4-(4-cMorophenyl)-l,3-oxazol-5-yl]-N,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]- l,2-dihydropyridine-3-carboxamide; 5-[2-amino-5-(4-cyanophenyl)-l,3-thiazol-4-yl]-N,6-dimethyl-2-oxo-l-[3-
(trifluoromethyl)phenyl]-l,2-dihydropyridine-3-carboxaniide; l-(3-chloro-4-fluorophenyl)-5-[l-(4-cyanophenyl)-lH-pyrazol-5-yl]-N,6-dimetliyl-2-oxo-
1 ,2-dihydropyridine-3-carboxamide;
5-[2-(4-chloro-phenyl)-2H-pyrazol-3-yl]-6-methyl-2-oxo-l-(3-trifluoromethyl-phenyl)- l,2-dihydro-pyridine-3-carboxylic acid methylamide;
5- [2-(4-fluoro-pheny l)-2H-pyrazol-3 -y 1] -6-methyl-2-oxo- 1 -(3 -trifluoromethyl-phenyl)- 1 ,2- dihydro-pyridine-3-carboxylic acid methylamide;
5-[3-(4-cyano-phenyl)-3H-[l,2,3]triazol-4-yl]-6-methyl-2-oxo-l-(3-trifluoromethyl- phenyl)-l,2-dihydro-pyridine-3-carboxylic acid methylamide; and
5-[l-(4-cyanophenyl)-lΗ-l,2,4-triazol-5-yl]-N,6-dimethyl-2-oxo-l-[3-
(trifluoromethyl)phenyl]-l,2-dihydropyridine-3-carboxamide; and pharmaceutically acceptable salts of any one thereof.
The present invention further provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined above which comprises,
(a) reacting a compound of formula (II)
Figure imgf000023_0001
(H) wherein L represents a leaving group (such as halogen or hydroxyl) and R 5 R 5 R 5 R and W are as defined in formula (I), with a compound of formula
Figure imgf000024_0001
4 5 wherein X, R and R are as defined in formula (I); or
(b) reacting a compound of formula (IV)
Figure imgf000024_0002
(IV) wherein Hal represents a halogen atom and X, R , R , R , R and R are as defined in foπnula (I),
14 14 with a nucleophile R -W-M wherein R and W are as defined in formula (I) and M represents an organo-tin or organo boronic acid group; or
(c) when W represents thiazolyl or oxazolyl, reacting a compound of formula (V)
Figure imgf000024_0003
(V)
1 3 4 5 6 14 wherein X5 R , R , R , R , R and R are as defined in formula (I), with thiourea or formamide respectively; and optionally after (a), (b) or (c) carrying out one or more of the following:
• converting the compound obtained to a further compound of the invention
• forming a pharmaceutically acceptable salt of the compound.
In process (a), the reaction may conveniently be carried out in an organic solvent such as dichloromethane or N-methylpyrrolidinone at a temperature, for example, in the range from 0 °C to the boiling point of the solvent. If necessary or desired, a base and/or a coupling reagent such as HATU (O-(7-Azabenzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate), HOAT (l-Hydroxy-7-azabenzotriazole), HOBT (1-Hydroxybenzotriazole hydrate) or DIEA (N,N-Diisopropylethylamine) may be added.
In process (b), the reaction may conveniently be carried out in an organic solvent such as DMF, NMP or toluene or a mixture thereof at elevated temperature (i.e. above ambient temperature, 200C), for example, in the range from 50 0C to 150 °C and in the presence of a suitable transition metal catalyst such as bis(tri-t-butylphosphine)palladium. If necessary or desired, a base such as potassium carbonate may be added.
In process (c), the reaction may conveniently be carried out by heating together the two starting materials in a suitable organic solvent such as acetonitrile at a temperature, for example, in the range from 50 0C to 150 0C.
Specific processes for the preparation of compounds of Formula (I) are disclosed within the Examples section of the present specification. Such processes form an aspect of the present invention.
The necessary starting materials are either commercially available, are known in the literature or may be prepared using known techniques. Specific processes for the preparation of certain key starting materials are disclosed within the Examples section of the present specification and such processes form an aspect of the present invention. Certain intermediates of formulae (II), (IV) and (V) are novel. Such novel intermediates form another aspect of the invention.
Compounds of formula (I) can be converted into further compounds of formula (I) using standard procedures.
It will be appreciated by those skilled in the art that in the processes of the present invention certain functional groups such as hydroxyl or amino groups may need to be protected by protecting groups. Thus, the preparation of the compounds of formula (I) may involve, at an appropriate stage, the addition and/or removal of one or more protecting groups.
The protection and deprotection of functional groups is described in 'Protective Groups in Organic Chemistry', edited by J.W.F. McOmie, Plenum Press (1973) and 'Protective Groups in Organic Synthesis', 3rd edition, T.W. Greene and P.G.M. Wuts, Wiley- Interscience (1999).
The compounds of formula (I) above may be converted to a pharmaceutically acceptable salt thereof, preferably an acid addition salt such as a hydrochloride, hydrobromide, sulphate, phosphate, acetate, fumarate, maleate, tartrate, lactate, citrate, pyruvate, succinate, oxalate, methanesulphonate
Figure imgf000026_0001
Compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers (including atropisomers) of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention. Enantiomerically pure forms are particularly desired.
The compounds of formula (T) and their pharmaceutically acceptable salts have activity as pharmaceuticals, in particular as modulators of serine proteases such as proteinase 3 and pancreatic elastase and, especially, human neutrophil elastase, and may therefore be beneficial in the treatment or prophylaxis of inflammatory diseases and conditions. The compounds of formula (I) and their pharmaceutically acceptable salts can be used in the treatment of diseases of the respiratory tract such as obstructive diseases of the airways including: asthma, including bronchial, allergic, intrinsic, extrinsic, exercise-induced, drug- induced (including aspirin and NS AID-induced) and dust-induced asthma, both intermittent and persistent and of all severities, and other causes of airway hyper- responsiveness; chronic obstructive pulmonary disease (COPD); bronchitis, including infectious and eosinophilic bronchitis; emphysema; bronchiectasis; cystic fibrosis; sarcoidosis; farmer's lung and related diseases; hypersensitivity pneumonitis; lung fibrosis, including cryptogenic fibrosing alveolitis, idiopathic interstitial pneumonias, fibrosis complicating anti-neoplastic therapy and chronic infection, including tuberculosis and aspergillosis and other fungal infections; complications of lung transplantation; vasculitic and thrombotic disorders of the lung vasculature, and pulmonary hypertension; antitussive activity including treatment of chronic cough associated with inflammatory and secretory conditions of the airways, and iatrogenic cough; acute and chronic rhinitis including rhinitis medicamentosa, and vasomotor rhinitis; perennial and seasonal allergic rhinitis including rhinitis nervosa (hay fever); nasal polyposis; acute viral infection including the common cold, and infection due to respiratory syncytial virus, influenza, coronavirus (including SARS) and adenovirus.
The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of bone and joints such as arthritides associated with or including osteoarthritis/osteoarthrosis, both primary and secondary to, for example, congenital hip dysplasia; cervical and lumbar spondylitis, and low back and neck pain; rheumatoid arthritis and Still's disease; seronegative spondyloarthropathies including ankylosing spondylitis, psoriatic arthritis, reactive arthritis and undifferentiated spondarthropathy; septic arthritis and other infection-related arthopathies and bone disorders such as tuberculosis, including Potts' disease and Poncet's syndrome; acute and chronic crystal- induced synovitis including urate gout, calcium pyrophosphate deposition disease, and calcium apatite related tendon, bursal and synovial inflammation; Behcet's disease; primary and secondary Sjogren's syndrome; systemic sclerosis and limited scleroderma; systemic lupus erythematosus, mixed connective tissue disease, and undifferentiated connective tissue disease; inflammatory myopathies including dermatomyositits and polymyositis; polymalgia rheumatica; juvenile arthritis including idiopathic inflammatory arthritides of whatever joint distribution and associated syndromes, and rheumatic fever and its systemic complications; vasculitides including giant cell arteritis, Takayasu's arteritis, Churg-Strauss syndrome, polyarteritis nodosa, microscopic polyarteritis, and . vasculitides associated with viral infection, hypersensitivity reactions, cryoglobulins, and paraproteins; low back pain; Familial Mediterranean fever, Muckle-Wells syndrome, and Familial Hibernian Fever, Kikuchi disease; drug-induced arthalgias, tendonititides, and myopathies.
The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of pain and connective tissue remodelling of musculoskeletal disorders due to injury [for example, sports injury] or disease: arthitides (for example rheumatoid arthritis, osteoarthritis, gout or crystal arthropathy), other joint disease (such as intervertebral disc degeneration or temporomandibular joint degeneration), bone remodelling disease (such as osteoporosis, Paget's disease or osteonecrosis), polychondritits, scleroderma, mixed connective tissue disorder, spondyloarthropathies or periodontal disease (such as periodontitis).
The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of skin such as psoriasis, atopic dermatitis, contact dermatitis or other eczematous dermatoses, and delayed-type hypersensitivity reactions; phyto- and photodermatitis; seborrhoeic dermatitis, dermatitis herpetiformis, lichen planus, lichen sclerosus et atrophica, pyoderma gangrenosum, skin sarcoid, discoid lupus erythematosus, pemphigus, pemphigoid, epidermolysis bullosa, urticaria, angioedema, vasculitides, toxic erythemas, cutaneous eosinophilias, alopecia areata, male-pattern baldness, Sweet's syndrome, Weber-Christian syndrome, erythema multiforme; cellulitis, both infective and non-infective; panniculitis;cutaneous lymphomas, non-melanoma skin cancer and other dysplastic lesions; drug-induced disorders including fixed drug eruptions.
The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the eye such as blepharitis; conjunctivitis, including perennial and vernal allergic conjunctivitis; iritis; anterior and posterior uveitis; choroiditis; autoimmune; degenerative or inflammatory disorders affecting the retina; ophthalmitis including sympathetic ophthalmitis; sarcoidosis; infections including viral , fungal, and bacterial.
The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the gastrointestinal tract such as glossitis, gingivitis, periodontitis; oesophagitis, including reflux; eosinophilic gastro-enteritis, mastocytosis, Crohn's disease, colitis including ulcerative colitis, proctitis, pruritis ani; coeliac disease, irritable bowel syndrome, non-inflammatory diarrhoea, and food-related allergies which may have effects remote from the gut (for example, migraine, rhinitis or eczema).
The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in the treatment of diseases of the cardiovascular system such as atherosclerosis, affecting the coronary and peripheral circulation; pericarditis; myocarditis , inflammatory and autoimmune cardiomyopathies including myocardial sarcoid; ischaemic reperfusion injuries; endocarditis, valvulitis, and aortitis including infective (for example syphilitic); vasculitides; disorders of the proximal and peripheral veins including phlebitis and thrombosis, including deep vein thrombosis and complications of varicose veins.
The compounds of formula (I) and their pharmaceutically acceptable salts can also be used in oncology such as in the treatment of common cancers including prostate, breast, lung, ovarian, pancreatic, bowel and colon, stomach, skin and brain tumors and malignancies affecting the bone marrow (including the leukaemias) and lymphoproliferative systems, such as Hodgkin's and non-Hodgkin's lymphoma; including the prevention and treatment of metastatic disease and tumour recurrences, and paraneoplastic syndromes.
In particular, the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis and gastric mucosal injury.
More particularly, the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of chronic obstructive pulmonary disease (COPD), asthma and rhinitis.
Even more particularly, the compounds of formula (I) and their pharmaceutically acceptable salts may be used in the treatment of chronic obstructive pulmonary disease (COPD).
Thus, the present invention provides a compound of formula (I) or a pharmaceutically- acceptable salt thereof as hereinbefore defined for use in therapy.
In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in therapy.
In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of neutrophil elastase activity is beneficial.
In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in the treatment of an inflammatory disease or condition.
In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in treating adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury.
In a further aspect, the present invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined in the manufacture of a medicament for use in treating chronic obstructive pulmonary disease (COPD).
In the context of the present specification, the term "therapy" also includes "prophylaxis" unless there are specific indications to the contrary. The terms "therapeutic" and "therapeutically" should be construed accordingly.
Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the disease or condition in question. Persons at risk of developing a particular disease or condition generally include those having a family history of the disease or condition, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the disease or condition.
The invention also provides a method of treating, or reducing the risk of, a disease or condition in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
The invention still further provides a method of treating, or reducing the risk of, an inflammatory disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
The invention still further provides a method of treating, or reducing the risk of, adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
The invention still further provides a method of treating, or reducing the risk of, chronic obstructive pulmonary disease (COPD) which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined.
For the above-mentioned therapeutic uses the dosage administered will, of course, vary with the compound employed, the mode of administration, the treatment desired and the disorder indicated. The daily dosage of the compound of the invention may be in the range from 0.05 mg/kg to 100 mg/kg.
The compounds of formula (I) and pharmaceutically acceptable salts thereof may be used on their own but will generally be administered in the form of a pharmaceutical composition in which the formula (I) compound/salt (active ingredient) is in association with a pharmaceutically acceptable adjuvant, diluent or carrier. Conventional procedures for the selection and preparation of suitable pharmaceutical formulations are described in, for example, "Pharmaceuticals - The Science of Dosage Form Designs", M. E. Aulton, Churchill Livingstone, 1988.
Depending on the mode of administration, the pharmaceutical composition will preferably comprise from 0.05 to 99 %w (per cent by weight), more preferably from 0.05 to 80 %w, still more preferably from 0.10 to 70 %w, and even more preferably from 0.10 to 50 %w, of active ingredient, all percentages by weight being based on total composition.
The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined, in association with a pharmaceutically acceptable adjuvant, diluent or carrier. The invention further provides a process for the preparation of a pharmaceutical composition of the invention which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as hereinbefore defined with a pharmaceutically acceptable adjuvant, diluent or carrier.
The pharmaceutical compositions may be administered topically (e.g. to the skin or to the lung and/or airways) in the form, e.g., of creams, solutions, suspensions, heptafluoroalkane (HFA) aerosols and dry powder formulations, for example, formulations in the inhaler device known as the Turbuhaler®; or systemically, e.g. by oral administration in the form of tablets, capsules, syrups, powders or granules; or by parenteral administration in the form of solutions or suspensions; or by subcutaneous administration; or by rectal administration in the form of suppositories; or transdermally.
Dry powder formulations and pressurized HFA aerosols of the compounds of the invention may be administered by oral or nasal inhalation. For inhalation, the compound is desirably finely divided. The finely divided compound preferably has a mass median diameter of less than 10 μm, and may be suspended in a propellant mixture with the assistance of a dispersant, such as a CS-C20 fatty acid or salt thereof, (for example, oleic acid), a bile salt, a phospholipid, an alkyl saccharide, a perfluorinated or polyethoxylated surfactant, or other pharmaceutically acceptable dispersant.
The compounds of the invention may also be administered by means of a dry powder inhaler. The inhaler may be a single or a multi dose inhaler, and may be a breath actuated dry powder inhaler.
One possibility is to mix the finely divided compound of the invention with a carrier substance, for example, a mono-, di- or polysaccharide, a sugar alcohol, or another polyol. Suitable carriers are sugars, for example, lactose, glucose, raffinose, melezitose, lactitol, maltitol, trehalose, sucrose, mannitol; and starch. Alternatively the finely divided compound may be coated by another substance. The powder mixture may also be dispensed into hard gelatine capsules, each containing the desired dose of the active compound.
Another possibility is to process the finely divided powder into spheres which break up during the inhalation procedure. This spheronized powder may be filled into the drug reservoir of a multidose inhaler, for example, that known as the Turbuhaler® in which a dosing unit meters the desired dose which is then inhaled by the patient. With this system the active ingredient, with or without a carrier substance, is delivered to the patient.
For oral administration the compound of the invention may be admixed with an adjuvant or a carrier, for example, lactose, saccharose, sorbitol, mannitol; a starch, for example, potato starch, corn starch or amylopectin; a cellulose derivative; a binder, for example, gelatine or polyvinylpyrrolidone; and/or a lubricant, for example, magnesium stearate, calcium stearate, polyethylene glycol, a wax, paraffin, and the like, and then compressed into tablets. If coated tablets are required, the cores, prepared as described above, may be coated with a concentrated sugar solution which may contain, for example, gum arabic, gelatine, talcum and titanium dioxide. Alternatively, the tablet may be coated with a suitable polymer dissolved in a readily volatile organic solvent.
For the preparation of soft gelatine capsules, the compound of the invention may be admixed with, for example, a vegetable oil or polyethylene glycol. Hard gelatine capsules may contain granules of the compound using either the above-mentioned excipients for tablets. Also liquid or semisolid formulations of the compound of the invention may be filled into hard gelatine capsules.
Liquid preparations for oral application may be in the form of syrups or suspensions, for example, solutions containing the compound of the invention, the balance being sugar and a mixture of ethanol, water, glycerol and propylene glycol. Optionally such liquid preparations may contain colouring agents, flavouring agents, saccharine and/or carboxymethylcellulose as a thickening agent or other excipients known to those skilled in art. The compounds of the invention may also be administered in conjunction with other compounds used for the treatment of the above conditions.
Thus, the invention further relates to combination therapies wherein a compound of the invention, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition or formulation comprising a compound of the invention, is administered concurrently or sequentially or as a combined preparation with another therapeutic agent or agents, for the treatment of one or more of the conditions listed. In particular, for the treatment of the inflammatory diseases such as (but not restricted to) rheumatoid arthritis, osteoarthritis, asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD), psoriasis, and inflammatory bowel disease, the compounds of the invention may be combined with agents listed below.
Non-steroidal anti-inflammatory agents (hereinafter NSAIDs) including non-selective cyclo-oxygenase COX-I / COX-2 inhibitors whether applied topically or systemically (such as piroxicam, diclofenac, propionic acids such as naproxen, flurbiprofen, fenoprofen, ketoprofen and ibuprofen, fenamates such as mefenamic acid, indomethacin, sulindac, azapropazone, pyrazolones such as phenylbutazone, salicylates such as aspirin); selective COX-2 inhibitors (such as meloxicam, celecoxib, rofecoxib, valdecoxib, lumarocoxib, parecoxib and etoricoxib); cyclo-oxygenase inhibiting nitric oxide donors (CINODs); glucocorticosteroids (whether administered by topical, oral, intramuscular, intravenous, or intra-articular routes); methotrexate; leflunomide; hydroxychloroquine; d-penicillamine; auranofin or other parenteral or oral gold preparations; analgesics; diacerein; intra-articular therapies such as hyaluronic acid derivatives; and nutritional supplements such as glucosamine. The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a cytokine or agonist or antagonist of cytokine function, (including agents which act on cytokine signalling pathways such as modulators of the SOCS system) including alpha-, beta-, and gamma- interferons; insulin-like growth factor type I (IGF-I); interleukins (IL) including ILl to 23, and interleukin antagonists or inhibitors such as anakinra; tumour necrosis factor alpha (TNF-α) inhibitors such as anti-TNF monoclonal antibodies (for example infliximab; adalimumab, and CDP-870) and TNF receptor antagonists including immunoglobulin molecules (such as etanercept) and low-molecular-weight agents such as pentoxyfylline. In addition the invention relates to a combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a monoclonal antibody targeting B-
5 Lymphocytes (such as CD20 (rituximab), MRA-aIL16R and T-Lymphocytes, CTLA4-Ig, HuMax 11-15).
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a modulator of chemokine receptor function such as an antagonist of CCRl, CCR2, CCR2A, CCR2B, CCR3, CCR4, o CCR5, CCR6, CCR7, CCR8, CCR9, CCRlO and CCRl 1 (for the C-C family); CXCRl,
CXCR2, CXCR3, CXCR4 and CXCR5 (for the C-X-C family) and CX3CRl for the C-X3-
C family.
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an inhibitor of matrix metalloprotease s (MMPs), i.e., the stromelysins, the collagenases, and the gelatinases, as well as aggrecanase; especially collagenase-1 (MMP-I), collagenase-2 (MMP-8), collagenase-3 (MMP- 13), stromelysin-1 (MMP-3), stromelysin-2 (MMP-IO), and stromelysin-3 (MMP- 11) and MMP-9 and MMP- 12, including agents such as doxycycline. The present invention still further relates to the combination of a compound of the 0 invention, or a pharmaceutically acceptable salt thereof, and a leukotriene biosynthesis inhibitor, 5-lipoxygenase (5-LO) inhibitor or 5-lipoxygenase activating protein (FLAP) antagonist such as; zileuton; ABT-761; fenleuton; tepoxalin; Abbott-79175; Abbott-85761; a N-(5-substituted)-thiophene-2-alkylsulfonamide; 2,6-di-tert-butylphenolhydrazones; a methoxytetrahydropyrans such as Zeneca ZD-2138; the compound SB-210661; a 5 pyridinyl-substituted 2-cyanonaphthalene compound such as L-739,010; a 2- cyanoquinoline compound such as L-746,530; or an indole or quinoline compound such as MK-591, MK-886, and BAY x 1005.
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a receptor antagonist for leukotrienes (LT) o B4, LTC4, LTD4, and LTE4. selected from the group consisting of the phenothiazin-3-ls such as L-651,392; amidino compounds such as CGS-25019c; benzoxalamines such as ontazolast; benzenecarboximidamides such as BIIL 284/260; and compounds such as zafirlukast, ablukast, montelukast, pranlukast, verlukast (MK-679), RG-12525, Ro-245913, iralukast (CGP 45715A), and BAY x 7195.
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a phosphodiesterase (PDE) inhibitor such as a methylxanthanine including theophylline and aminophylline; a selective PDE isoenzyme inhibitor including a PDE4 inhibitor an inhibitor of the isoform PDE4D, or an inhibitor of PDE5.
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a histamine type 1 receptor antagonist such as cetirizine, loratadine, desloratadine, fexofenadine, acrivastine, terfenadine, astemizole, azelastine, levocabastine, chlorpheniramine, promethazine, cyclizine, or mizolastine; applied orally, topically or parenterally.
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a proton pump inhibitor (such as omeprazole) or a gastroprotective histamine type 2 receptor antagonist.
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an antagonist of the histamine type 4 receptor.
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an alpha- l/alpha-2 adrenoceptor agonist vasoconstrictor sympathomimetic agent, such as propylhexedrine, phenylephrine, phenylpropanolamine, ephedrine, pseudoephedrine, naphazoline hydrochloride, oxymetazoline hydrochloride, tetrahydrozoline hydrochloride, xylometazoline hydrochloride, tramazoline hydrochloride or ethylnorepinephrine hydrochloride.
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an anticholinergic agents including muscarinic receptor (Ml, M2, and M3) antagonist such as atropine, hyoscine, glycopyrrrolate, ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine.
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a beta-adrenoceptor agonist (including beta receptor subtypes 1-4) such as isoprenaline, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, or pirbuterol, or a chiral enantiomer thereof. The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a chromone, such as sodium cromoglycate or nedocromil sodium.
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with a glucocorticoid, such as flunisolide, triamcinolone acetonide, beclomethasone dipropionate, budesonide, fluticasone propionate, ciclesonide or mometasone furoate.
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, with an agent that modulates a nuclear hormone receptor such as PPARs. The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an immunoglobulin (Ig) or Ig preparation or an antagonist or antibody modulating Ig function such as anti-IgE (for example omalizumab).
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and another systemic or topically-applied anti- inflammatory agent, such as thalidomide or a derivative thereof, a retinoid, dithranol or calcipotriol.
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and combinations of aminosalicylates and sulfapyridine such as sulfasalazine, mesalazine, balsalazide, and olsalazine; and immunomodulatory agents such as the thiopurines, and corticosteroids such as budesonide.
The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with an antibacterial agent such as a penicillin derivative, a tetracycline, a macrolide, a beta-lactam, a fluoroquinolone, metronidazole, an inhaled aminoglycoside; an antiviral agent including acyclovir, famciclovir, valaciclovir, ganciclovir, cidofovir, amantadine, rimantadine, ribavirin, zanamavir and oseltamavir; a protease inhibitor such as indinavir, nelfinavir, ritonavir, and saquinavir; a nucleoside reverse transcriptase inhibitor such as didanosine, lamivudine, stavudine, zalcitabine or zidovudine; or a non-nucleoside reverse transcriptase inhibitor such as nevirapine or efavirenz. The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a cardiovascular agent such as a calcium channel blocker, a beta-adrenoceptor blocker, an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin-2 receptor antagonist; a lipid lowering agent such as a statin or a fibrate; a modulator of blood cell morphology such as pentoxyfylline; thrombolytic, or an anticoagulant such as a platelet aggregation inhibitor. The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and a CNS agent such as an antidepressant (such as sertraline), an anti-Parkinsonian drug (such as deprenyl, L-dopa, ropinirole, pramipexole, a MAOB inhibitor such as selegine and rasagiline, a comP inhibitor such as tasmar, an A-2 inhibitor, a dopamine reuptake inhibitor, an NMDA antagonist, a nicotine agonist, a dopamine agonist or an inhibitor of neuronal nitric oxide synthase), or an anti- Alzheimer's drug such as donepezil, rivastigmine, tacrine, a COX-2 inhibitor, propentofylline or metrifonate.
The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, and an agent for the treatment of acute or chronic pain, such as a centrally or peripherally-acting analgesic (for example an opioid or derivative thereof), carbamazepine, phenytoin, sodium valproate, amitryptiline or other anti-depressant agent-s, paracetamol, or a non-steroidal anti-inflammatory agent. The present invention further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a parenterally or topically-applied (including inhaled) local anaesthetic agent such as lignocaine or a derivative thereof. A compound of the present invention, or a pharmaceutically acceptable salt thereof, can also be used in combination with an anti-osteoporosis agent including a hormonal agent such as raloxifene, or a biphosphonate such as alendronate. The present invention still further relates to the combination of a compound of the invention, or a pharmaceutically acceptable salt thereof, together with a: (i) tryptase inhibitor; (ii) platelet activating factor (PAF) antagonist; (iii) interleukin converting enzyme (ICE) inhibitor; (iv) IMPDH inhibitor; (v) adhesion molecule inhibitors including VLA-4 antagonist; (vi) cathepsin; (vii) kinase inhibitor such as an inhibitor of tyrosine kinase (such as Btk, Itk, Jak3 or MAP, for example Gefitinib or Imatinib mesylate), a serine / threonine kinase (such as an inhibitor of a MAP kinase such as p38, JTSfK, protein kinase A, B or C, or IKK), or a kinase involved in cell cycle regulation (such as a cylin dependent kinase); (viii) glucose-6 phosphate dehydrogenase inhibitor; (ix) kinin-B.subl . - or B.sub2. -receptor antagonist; (x) anti-gout agent, for example colchicine; (xi) xanthine oxidase inhibitor, for example allopurinol; (xii) uricosuric agent, for example probenecid, sulfinpyrazone or benzbromarone; (xiii) growth hormone secretagogue; (xiv) transforming growth factor (TGFβ); (xv) platelet-derived growth factor (PDGF); (xvi) fibroblast growth factor for example basic fibroblast growth factor (bFGF); (xvii) granulocyte macrophage colony stimulating factor (GM-CSF); (xviii) capsaicin cream; (xix) tachykinin NK. sub 1. or NK.sub3. receptor antagonist such as NKP-608C, SB-233412 (talnetant) or D-4418; (xx) elastase inhibitor such as UT-77 or ZD-0892; (xxi) TNF-alpha converting enzyme inhibitor (TACE); (xxii) induced nitric oxide synthase (iNOS) inhibitor; (xxiii) chemoattractant receptor-homologous molecule expressed on TH2 cells, (such as a CRTH2 antagonist); (xxiv) inhibitor of P38; (xxv) agent modulating the function of Toll-like receptors (TLR), (xxvi) agent modulating the activity of purinergic receptors such as P2X7; or (xxvii) inhibitor of transcription factor activation such as NFkB, API, or STATS. A compound of the invention, or a pharmaceutically acceptable salt thereof, can also be used in combination with an existing therapeutic agent for the treatment of cancer, for example suitable agents include:
(i) an antiproliferative/antineoplastic drug or a combination thereof, as used in medical oncology, such as an alkylating agent (for example cis-platin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulphan or a nitrosourea); an antimetabolite (for example an antifolate such as a fluoropyrimidine like 5-fluorouracil or tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea, gemcitabine or paclitaxel); an antitumour antibiotic (for example an anthracycline such as adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin or mithramycin); an antimitotic agent (for example a vinca alkaloid such as vincristine, vinblastine, vindesine or vinorelbine, or a taxoid such as taxol or taxotere); or a topoisomerase inhibitor (for example an epipodophyllotoxin such as etoposide, teniposide, amsacrine, topotecan or a camptothecin); (ii) a cytostatic agent such as an antioestrogen (for example tamoxifen, toremifene, raloxifene, droloxifene or iodoxyfene), an oestrogen receptor down regulator (for example fulvestrant), an antiandrogen (for example bicalutamide, flutamide, nilutamide or cyproterone acetate), a LHRH antagonist or LHRH agonist (for example goserelin, leuprorelin or buserelin), a progestogen (for example megestrol acetate), an aromatase inhibitor (for example as anastrozole, letrozole, vorazole or exemestane) or an inhibitor of 5α-reductase such as finasteride;
(iii) an agent which inhibits cancer cell invasion (for example a metalloproteinase inhibitor like marimastat or an inhibitor of urokinase plasminogen activator receptor function); (iv) an inhibitor of growth factor function, for example: a growth factor antibody (for example the anti-erbb2 antibody trastuzumab, or the anti-erbbl antibody cetuximab [C225]), a farnesyl transferase inhibitor, a tyrosine kinase inhibitor or a serine/threonine kinase inhibitor, an inhibitor of the epidermal growth factor family (for example an EGFR family tyrosine kinase inhibitor such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3- morpholinopropoxy)quinazolin-4-amine (gefitinib, AZDl 839), N-(3-ethynylphenyl)-6,7- bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) or 6-acrylamido-N-(3- chloro-4-fluorophenyl)-7-(3-morpholinopropoxy)quinazolin-4-amine (CI 1033)), an inhibitor of the platelet-derived growth factor family, or an inhibitor of the hepatocyte growth factor family; (v) an antiangiogenic agent such as one which inhibits the effects of vascular endothelial growth factor (for example the anti-vascular endothelial cell growth factor antibody bevacizumab, a compound disclosed in WO 97/22596, WO 97/30035, WO 97/32856 or WO 98/13354), or a compound that works by another mechanism (for example linomide, an inhibitor of integrin αvβ3 function or an angiostatin); (vi) a vascular damaging agent such as combretastatin A4, or a compound disclosed in WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 or WO 02/08213; (vii) an agent used in antisense therapy, for example one directed to one of the targets listed above, such as ISIS 2503, an anti-ras antisense; (viii) an agent used in a gene therapy approach, for example approaches to replace aberrant genes such as aberrant p53 or aberrant BRCAl or BRCA2, GDEPT (gene-directed enzyme pro-drug therapy) approaches such as those using cytosine deaminase, thymidine kinase or a bacterial nitroreductase enzyme and approaches to increase patient tolerance to chemotherapy or radiotherapy such as multi-drag resistance gene therapy; or (ix) an agent used in an immunotherapeutic approach, for example ex-vivo and in- vivo approaches to increase the immunogenicity of patient tumour cells, such as transfection with cytokines such as interleukin 2, interleukin 4 or granulocyte-macrophage colony stimulating factor, approaches to decrease T-cell anergy, approaches using transfected immune cells such as cytokine-transfected dendritic cells, approaches using cytokine-transfected tumour cell lines and approaches using anti-idiotypic antibodies.
In particular the compounds of the invention may be administered in conjunction with a second active ingredient which is selected from: a) a PDE4 inhibitor including an inhibitor of the isoform PDE4D; b) a β-adrenoceptor agonist such as metaproterenol, isoproterenol, isoprenaline, albuterol, salbutamol, formoterol, salmeterol, terbutaline, orciprenaline, bitolterol mesylate, pirbuterol or indacaterol; c) a muscarinic receptor antagonist (for example a Ml , M2 or M3 antagonist, such as a selective M3 antagonist) such as ipratropium bromide, tiotropium bromide, oxitropium bromide, pirenzepine or telenzepine; d) a modulator of chemokine receptor function (such as a CCRl or CCR8 receptor antagonist); e) an inhibitor of kinase function; f) a non-steroidal glucocorticoid receptor agonist; g) a steroidal glucocorticoid receptor agonist; and h) a protease inhibitor (such as a MMP 12 or MMP9 inhibitor);
The present invention will now be further explained by reference to the following illustrative examples.
General Methods 1H NMR and 13C NMR spectra were recorded on a Varian Inova 400 MHz or a Varian Mercwγ-YX 300 MHz instrument. The central peaks of chloroform-β? (δπ 7.27 ppm), dimethylsulfoxide-^ (δH 2.50 ppm), acetonitrile-^ (δH 1.95 ppm) or methanol-^ (δH 3.31 ppm) were used as internal references. Column chromatography was carried out using silica gel (0.040-0.063 mm, Merck). Unless stated otherwise, starting materials were commercially available. AU solvents and commercial reagents were of laboratory grade and were used as received.
The following method was used for LC/MS analysis:
Instrument Agilent 1100; Column Waters Symmetry 2.1 x 30 mm; Mass APCI; Flow rate 0.7 ml/min; Wavelength 254 nm; Solvent A: water + 0.1% TFA; Solvent B: acetonitrile + 0.1% TFA ; Gradient 15-95%/B 8 min, 95% B 1 min.
Analytical chromatography was run on a Symmetry C18-column, 2.1 x 30 mm with 3.5 μm particle size, with acetonitrile/water/0.1% trifluoroacetic acid as mobile phase in a gradient from 5% to 95% acetonitrile over 8 minutes at a flow of 0.7 ml/min.
The abbreviations or terms used in the examples have the following meanings:
HATU: O-(7-Azabenzotriazol-l-yl)-N,N,N',Nf-tetramethyluronium hexafluorophosphate
HOAT: 1 -Hydroxy -7-azabenzotriazole
NMP : 1 -N-Methy 1-2-pyrrolidinone
THF: Tetrahydrofuran
DCM: Dichloromethane
DIEA: N,N-Diisopropylethylamine
DME: 1,2-Dimethoxyethane
EtOAc: Ethyl acetate
DMSO: Dimethyl sulphoxide
SM: Starting material
Ex: Example
Aq: Aqueous
RT: Room temperature
Example 1 5-ri-(4-CvanophenylVlH-pyrazol-5-yll-JV.6-dimethyl-2-oxo-l-r3- ("trifluoromethyDphenyll - 1 ,2-dihvdropyridine-3 -carboxamide
Argon was bubbled through 5-iodo-iV,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]-l,2- dihydropyridine-3-carboxamide (SM2, 200 mg, 0.46 mmol) and [l-(4-cyanophenyl)-lH- pyrazol-5-yl]boronic acid (SM3, 150 mg, 0.70 mmol ) in DME (10 ml) and 2M Na2CO3 (5 ml) for 10 min. Palladium-tri-tert-butylphosphine (25 mg, 0.049 mmol) was added and the mixture was stirred under argon at 82 °C for 2h. More SM3 (150 mg, 0.70 mmol) and palladium-tri-tert-butylphosphine (10 mg, 0.019 mmol) were added and the mixture was stirred for a further 2h under the same conditions. The reaction mixture was then was cooled to RT, diluted with ethyl acetate (150 ml) and washed with brine (3 x 100 ml). The organic phase was dried (Na2SO4), filtered and evaporated. The residue was purified by ΗPLC on a Kromasil C-18 column using a gradient of acetonitrile/water. Freeze-drying of the mixture afforded the title compound (80 mg).
1H NMR (399.99 MHz, DMSO-D6) δ 9.18 (q, J = 4.78 Hz, IH), 8.05 (s, IH), 7.96 - 7.64 (mm, 9H), 6.72 (d, J= 1.76 Hz, IH), 2.76 (d, J= 4.77 Hz, 3H), 1.76 (s, 3H); APCI-MS m/z: 478.3 [MH+].
Example 2
The following compound was synthesised in an analogous manner to Example 1.
Figure imgf000044_0001
Example 3
5-r2-Aniino-5-r4-chlorophenvD-l,3-thiazol-4-vn-N.6-dimethyl-2-oxo-l-["3- (trifluoromethvDphenvn-l^-dihydropyridine-S-carboxamide Thiourea (8.5 mg, 0.11 mmol) was added to 5-[bromo(4-chlorophenyl)acetyl]-N,6- dimethyl-2-oxo- 1 - [3 -(trifluoromethyl)phenyl] - 1 ,2-dihy dropyridine-3 -carboxamide (SM4, 30 mg, 55 mmol) in acetonitrile (1 ml) and the mixture was heated in a microwave oven to 120 0C for 10 min. The crude product was purified on an Xterra C8 column using a gradient of acetonitrile/water. Freeze drying of the mixture afforded the title compound (10 mg, 35%).
1H NMR (400 MHz, DMSO-D6) δ 9.27 (d, J= 4.8 Hz, IH), 8.27 (s, IH), 7.88 (d, J= 8.0
Hz, 2H), 7.81 (t, J= 7.6 Hz, 3H), 7.67 (d, J= 7.8 Hz, IH), 7.37 (d, J= 8.5 Hz, 4H), 7.32 (s, 3H), 7.25 (d, J= 8.5 Hz, 2H), 2.77 (d, J= 4.6 Hz, 3H)3 1.67 (s, 3H);
APCI-MS m/z: 519.0 [MH+].
Examples 4 and 5
The following compounds were synthesised in an analogous manner to Example 3.
Figure imgf000046_0001
Example 6
The following compound was synthesised in an analogous manner to Example 1.
.1 -(3 -Chloro-4-fluorophenyiy 5 - \ 1 -(4-cy anophenyl)- 1 H-pyrazol-5 -yll -N,6-dimethy 1-2-oxo- 1 ,2-dihydropyridine-3-carboxamide
1H NMR (300 MHz5 DMSO-D6) δ 9.18 (q, IH)5 8.02 (s, IH)5 7.96-7.90 (m, 3H)5 7.78 (dd5 IH), 7.71-7.60 (m, 3H)5 7.43 (m, IH)5 6.70 (d, IH), 2.76 (d, 3H)5 1.81 (s, 3H); APCI-MS m/z: 462 [MH+]. Example 7
542-r4-CMoro-phenylV2H-pyrazol-3-yll-6-methyl-2-oxo-l-('3-trifluoromethyl-phenvD- O-dihydro-pyridine-B-carboxylic acid methylamide
a) 1 -(^-Chloro-phenylVS-tributylstannanyl- 1/f-pyrazole
2,2,6,6-Tetramethylpiperidine (TMP, 0.25 g, 1.78 mmol) was dissolved in dry THF (10 ml) in a flask with a magnetic stirrer bar. The flask was flushed with argon and kept under an inert atmosphere. The mixture was cooled to -78 0C, and n-BuLi (1.1 ml, 1.6M, 1.78 mmol) was added dropwise during 1 minute. The mixture was stirred for 5 minutes at this temperature, before adding a solution of l-(4-chloro-phenyl)-lH-pyrazole (0.21 g, 1.1 mmol) in dry TΗF (2 ml). The solution was added dropwise over 2 minutes, and the obtained solution was stirred at this temperature for 20 minutes, before adding Bu3SnCl (0.36 g, 1.1 mmol) over 1 minute. The solution was allowed to slowly warm to RT and was then quenched with MeOH (1 ml). The residual mixture was partitioned between EtOAc and water, and the organic phase was dried and concentrated. Purification on silica afforded 0.2 g (40%) of an oil.
1H NMR (400 MHz, DMSO-D6) δ 7.77 (d, J=I.8 Hz, IH), 7.62 (d, J= 9.0Hz, 2H), 7.42 (d, J=9.0 Hz, 2H), 6.54 (d, J=I.8 Hz, IH), 1.50-0.67 (m, 27H). APCI-MS m/z: 468 [MH+].
b) 5-["2-r4-Chloro-phenylV27f-pyrazol-3-yl]-6-methyl-2-oxo-l-r3-trifluoromethyl-phenylV l,2-dihydro-pyridine-3-carboxylic acid methylamide l-(4-Chloro-phenyl)-5-tributylstannanyl-lH"-pyrazole (0.107 g, 0.22 mmol), 5-iodo-6- methyl-2-oxo- 1 -(3-trifluoromethyl-phenyl)- 1 ,2-dihydro-pyridine-3-carboxylic acid methylamide (0.05 g, 0.11 mmol), Pd(PBu^)2 (10 mg) and DME (2 ml) were placed in a tube for microwave synthesis. The mixture was degassed with argon and heated in a synthesis microwave heater (CEM) at 100 0C (max 150W) for 10 minutes. The solvent was removed in vacuo giving a crude product which was purified on silica and then further purified on preparative ΗPLC. The pure fractions were freeze-dried giving 10 mg (17%) of the title compound. 1H NMR (400 MHz5 DMSO-D6) δ 9.23-9.12 (m, IH), 8.03 (s, IH), 7.91 (d, J=8.0 Hz3 IH),
7.87-7.80 (m, 3H), 7.69 (d, J=8.0 Hz, IH)5 7.53 (d, J= 8.8 Hz, 2H)5 7.45 (d, J= 8.8 Hz, 2H), 6.66 (d, J=I.8 Hz, IH)5 2.75 (d, J=4.8 Hz, 3H)5 1.77 (s, 3H).
APCI-MS m/z: 487.0 [MH+].
5
Example 8
5-["2-(4-Fluoro-phenvD-2H-pyrazol-3-yll-6-methyl-2-oxo-l-('3-trifluoromethyl-phenyl)- l^-dihydro-pyridine-S-carboxylic acid methylamide 0 a) 1 -^-Fluoro-phenylVS-tributylstannanyl-liJ'-pyrazole
The compound was prepared by an analogous procedure to that described in Example 7(a).
APCI-MS m/z: 452 [MH+].
s b) 5-[2-f4-Fluoro-phenylV2H-pyrazol-3-yll-6-methyl-2-oxo- 1 -f3-trifluoromethyl-phenviy l,2-dihydro-pyridine-3-carboxylic acid methylamide l-(4-Fluoro-phenyl)-5-tributylstannanyl-li/-pyrazole (0.100 g, 0.22 mmol), 5-iodo-6- metliyl-2-oxo- 1 -(3 -trifluoromethyl-phenyl)- 1 ,2-dihy dro-pyridine-3 -carboxylic acid methylamide (0.05 g, 0.11 mmol), Pd(PBuS)2 (10 mg) and DME (2 ml) were placed in a 0 tube for microwave synthesis. The mixture was degassed with argon and heated in a synthesis microwave heater (CEM) at 1000C (max 150W) for 10 minutes. The solvent was removed in vacuo giving a crude product which was purified on silica and then further purified on preparative HPLC. The pure fractions were freeze-dried giving 10 mg (17%) of the title compound. s 1H NMR (400 MHz, DMSO-D6) δ 9.22-9.13 (m, IH)5 8.04 (s, IH), 7.91 (d, J=7.7 Hz, IH),
7.86-7.80 (m, 3H)5 7.67 (d, J=7.7 Hz5IH), 7.49-7.42 (m, 2H)5 7.30 (t, J= 8.8 Hz5 2H)5 6.65 (d, J=1.8 Hz, IH)5 2.75 (d, J=4.8 Hz, 3H), 1.76 (s, 3H).
APCI-MS m/z: 471.0 [MH+].
0 Example 9
5-[-3-C4-Cvano-phenylV3H-π,231triazol-4-vn-6-methyl-2-oxo-l-('3-trifluoromethyl- phenviyi,2-dihvdro-pyridine-3-carboxyh'c acid methylamide
a) 4-Fl ,231Triazol-l-yl-benzonitrile
4-Fluorobenzonitrile (0.847 g, 7 mmol), IH-[1 ,2,3]triazole (0.483 g, 7 mmol), Cs2CO3 (2.27 g, 7 mmol) and DMF (8 ml) and a magnetic stirrer were placed in a vial. The mixture was heated with stirring for 3h at 80 0C. Extractive work-up (EtOAc/H2O) and subsequent drying (Na2SO4) gave a crude product which was purified on silica giving 0.55 g (46%) of the title compound.
1H NMR (400 MHz, DMSO-D6) δ 9.00 (d, J=1.2 Hz, IH), 8.18 (d, J=8.8 Hz5 2H), 8.11 (d, J=8.8 Hz, 2H), 8.05 (d, J=I .2 Hz, IH).
b) 4-(5-Tributylstannanyl-f 1 ,2,3]triazol- 1 -ylVbenzonitrile
4-[l,2,3]Triazol-l-yl-benzonitrile (0.105 g, 0.6 mmol) and dry THF (6 ml) and a magnetic stirrer were placed in a flask. The flask was flushed with argon and kept under an inert atmosphere and cooled to -78 0C. At this temperature, tert-BvdLi (0.36 ml, 1.7M, 0.6 mmol) was added dropwise during 1 to 2 minutes. The mixture was stirred at this temperature for 15 minutes and Bu3SnCl (0.19 g, 0.6 mmol) was added during 1 minute, and the mixture was then allowed to slowly reach RT. The crude mixture was directly purified on silica (heptane:EtOAc 4:1) giving 0.12 g (43%) of the title stannane.
APCI-MS m/z: 460 [MH+].
c) 5-r3-C4-Cyano-phenyl)-3H-n .2.31triazol-4-yll-6-methyl-2-oxo-l -(3-trifluoromethyl- phenviyi^-dihydro-pyridine-S-carboxylic acid methylamide
4-(5-Tributylstannanyl-[l5253]triazol-l-yl)-benzonitrile (0.107 g, 0.22 mmol), 5-iodo-6- methyl-2-oxo-l-(3-trifiuoromethyl-phenyl)-l,2-dihydro-pyridine-3-carboxylic acid methylamide (0.05 g, 0.11 mmol), Pd(PBul 3)2 (10 mg) and DME (2 ml) were placed in a tube for microwave synthesis. The mixture was degassed with argon and heated in a synthesis microwave heater (CEM) at 100 °C (max 150W) for 10 minutes. The solvent was removed in vacuo giving a crude product which was purified on silica and then further purified on preparative HPLC. The pure fractions were freeze-dried giving 20 mg (40%) of the title compound.
1H NMR (400 MHz, DMSO-D6) δ 9.17-9.09 (m, IH)5 8.12 (s, IH), 8.09-8.02 (m, 3H), 7.92 (d, J=7.8 Hz3 IH), 7.88-7.82 (m, 2H), 7.80 (d, J= 8.6 Hz32H), 7.80 (d, J= 8.0 Hz3 IH)3 2.74 (d, J=4.8 Hz3 3H)3 1.80 (s, 3H).
APCI-MS m/z: 479.0 [MH+].
Example 10
5-ri-(4-CvanophenylVlH-1.2.4-triazol-5-vn-K6-dimethyl-2-oxo-l-r3- (trifluoromethyl)phenyl]- 1 ,2-dihvdropyridine-3-carboxamide
5-Iodo-N36-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]-l,2-dihydropyridine-3- carboxamide (SM2, 0.051 g, 0.117 mmol), 4-(lH-l,234-triazol-l-yl)benzonitrile (0.020 g, 0.117 mmol), copper(I) iodide (0.044 g, 0.234 mmol), cesium fluoride (0.036 g, 0.234 mmol) and NMP (0.5 ml) were placed in a vial. Argon was bubbled through the stirred mixture for 10 min. Palladium(II) acetate (0.002 g, 0.0089 mmol) was added and the vial was sealed and stirred at 140 0C for 6h. Two more experiments were run the same way and the three reaction mixtures were combined and purified by preparative HPLC to give 0.003 g (2%) of the title compound.
1H NMR (400 MHz3 DMSO-D6) δ 9.16 - 9.09 (m, IH)3 8.42 (s, IH)3 8.16 (s, IH)3 8.01 (d,
J= 8.7 Hz3 2H)3 7.92 (d, J= 8.9 Hz3 2H)3 7.84 (t, J= 7.7 Hz3 IH), 7.80 - 7.74 (m, 3H)3 2.75 (d, J= 4.7 Hz3 3H)3 1.85 (s, 3H). APCI-MS m/z: 479.0 [MH+].
Preparation of Starting Materials
The starting materials for the examples above are either commercially available or are readily prepared by standard methods from known materials. For example, the following reactions are illustrations, but not a limitation, of the preparation of some of the starting materials.
Starting material SMl
5
5-Iodo-6-methyl-iV-[4-('methylsulfonvDbenzyl]-2-oxo-l-[3-('trifluoromethyl)phenyl1-l,2- dihvdropyridine-3 -carboxamide
To an ice-cooled solution of 3-(trifluoromethyl)aniline (64.5 g, 0.40 mol) and triethylamine (60 ml) in acetone (700 ml) was added dropwise, ethyl 3-chloro-3-oxopropanoate (63.6 g, o 0.42 mol) in acetone (50 ml). After the addition was complete (approx. 30 minutes), stirring was continued at RT overnight. The solvents were removed and water (1200 ml) was added. The resulting precipitate was filtered off, thoroughly washed twice with water and then dried to afford ethyl 3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propanoate as a yellow powder (109 g, 99%). s 1H NMR (399.99 MHz, CDCl3): δ 9.52 (IH, s); 7.87 (IH, s); 7.78 (IH, d); 7.46 (IH, t); 7.39 (IH, d); 4.29 (2H, q); 3.50 (2H5 s); 1.35 (3H, t). APCI-MS m/z: 276.1 [MH+].
To a solution of ethyl 3-oxo-3-{[3-(trifluoromethyl)phenyl]amino}propanoate (19.2 g, 70 Q mmol) and sodium methoxide (7.6 g, 140 mmol) in EtOH (250 ml) was added
4-methoxybut-3-en-2-one (90%) (7.72 g, 77 mmol). After the addition, the reaction mixture was refluxed for 2h and then cooled. Water (50 ml) and 2M NaOH were added and the mixture was stirred at RT overnight. The organic solvents were removed and the reaction mixture was extracted (washed) with EtOAc. The water phases were acidified 5 with hydrochloric acid to pH 3 to 4, an orange coloured precipitate appeared and was filtered off, washed with water and dried. Recrystallisation twice from heptane/EtOAc (4:1) afforded 6-metliyl-2-oxo- 1 - [3-(trifluoromethyl)phenyl]- 1 ,2-dihydropyridine-3- carboxylic acid (12 g, 58%) as a white powder.
1H NMR (399.99 MHz, CDCl3): δ 13.68 (IH, s); 8.54 (IH, d); 7.86 (IH, d); 7.79 (IH, t); o 7.55 (IH, brs); 7.48 (IH, d); 6.58 (IH, d); 2.16 (3H, s);
APCI-MS m/z: 298.1 [MH+]. A mixture of 6-methyl-2-oxo-l-[3-(trifluoromethyl)phenyl]-l,2-dihydropyridine-3- carboxylic acid (7.43 g, 25 mmol), HATU (10.5 g, 27.5 mmol), HOAT (3.75 g, 27.5 mmol) and DIEA (14.2 ml, 82.5 mmol) in NMP (65 ml) was reacted for Ih, then A-
5 methylsulphonylbenzyl amine hydrochloride (5.8 g, 26 mmol) was added. After Ih, the reaction mixture was slowly poured into stirred ice water (1 L). A powder was formed and the water mixture was acidified to pH 3 with 0.5M citric acid, and stirring was continued for Ih. The precipitate was filtered off, washed with water and dried in vacuum overnight. Recrystallisation from EtOAc gave 6-methyl-iV-[4-(methylsulfonyl)benzyl]-2-oxo-l-[3- o (trifluoromethyl)phenyl]-l,2-dihydropyridine-3-carboxamide (8.1 g, 70%).
1HNMR (399.99 MHz, CDCl3): δ 10.00 (IH, brt); 8.60 (IH, d); 7.88 (2H, d); 7.83 (IH, d); 7.76 (IH, t); 7.53 (3H, m); 7.46 (IH, d); 6.49 (IH, d); 4.68 (2H, m); 3.03 (3H, s); 2.10 (3H, s);
APCI-MS m/z: 465.1 [MH+]. 5
To a solution of 6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-l-[3- (trifluoroniethyl)phenyl]-l,2-dihydropyridine-3-carboxamide (200 mg, 0.43 mmol) in MeCN (1.5 ml) at RT and under argon, was added trifluoromethanesulfonic acid (1 ml) followed by JV-iodosuccinimide (97 mg, 0.43 mmol). After 45 min, the reaction mixture o was diluted with DCM, washed with aqueous NaHCO3, with aqueous NaS2O4 and water, dried (Na2SO4), and evaporated to give the title compound SMl (200 mg).
1HNMR (399.99 MHz5 CDCl3): δ 9.85 (IH5 brt); 8.90 (IH, d); 7.88 (2H, d); 7.76 (2H, m); 7.50 (2H, d); 7.48 (IH, s); 7.40 (IH, d); 4.65 (2H, m); 3.03 (3H, s); 2.32 (3H, s); APCI-MS m/z: 591.0 [MH+]. 5
Starting material SM2
SM2, 5-iodo-N,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]-l52-dihydropyridine-3- carboxamide, was synthesised in an analogous manner to SMl. 0 Starting material SM3
[ 1 -(4-CvanophenylV lH~-pyrazol-5-yriboronic acid 4-(lH-Pyrazol-l-yl)benzonitrile (Eur. J. Org. Chem. 2004, 695-709) (1.5 g, 8.87 mmol) in dry TΗF (50 ml) under argon was stirred at —78 °C whilst lithium diisopropylamide (1.8M solution in TΗF/hexane/ethyl benzene; 5.2 ml, 9.32 mmol) was added dropwise during 20 min. Stirring and cooling were continued for Ih, triisopropyl borate (8 ml, 34.5 mmol) was added dropwise during 30 min and then the temperature was allowed to rise overnight to RT. The pΗ of the reaction mixture was adjusted to 5 with IM HCl and the mixture was then concentrated to a minimum volume and extracted with ethyl acetate (200 ml) and brine (3 x 100 ml). The organic phase was collected, dried (Na2SO4), filtered and evaporated to give a brown solid (1.32 g) which was used in the next step without further purification.
APCI-MS m/z: 214.1 [MH+].
Starting Material SM4
5 - [Bromof 4-chloropheny Dacetyl] -JV,6-dimethyl-2-oxo- 1 - [3 -(trifluoromethyDphenyli -1,2- dihvdropyridine-3 -carboxamide A mixture of 5-iodo-iV,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]-l,2- dihydropyridine-3 -carboxamide (139 mg, 0.32 mmol), tetrakis(triphenylphophine) palladium(O) (1.8 mg, 1.6 μmol), copper(I) iodide (0.6 mg 3.2 μmol), l-chloro-4- ethynylbenzene (87 mg, 0.638 mmol) and DIEA (64 mg, 0.5 mmol) in acetonitrile (1.5 ml) was heated in a microwave oven to 70 ° C for 0.5h. After cooling, the reaction mixture was purified by flash chromatography to give 5-[(4-chlorophenyl)ethynyl]-iV,6-dimethyl-2- oxo-l-[3-(trifluoromethyl)phenyl]-l,2-dihydropyridine-3-carboxamide (111 mg, 78%).
APCI-MS m/z: 445.3 [MH+].
5-[(4-Chlorophenyl)ethynyl]-N,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)ρhenyl]-l,2- dihydropyridine-3-carboxamide (111 mg, 0.25 mmol) was mixed with formic acid (1 ml) and heated in a microwave oven to 120 °C for Ih. The formic acid was evaporated off and the residue was purified on an Xterra C 8 column using a gradient of acetonitrile/water. Freeze drying of the mixture afforded 5-[(4-chlorophenyl)acetyl]-iV,6-dimethyl-2-oxo-l- [3-(trifluoromethyl)phenyl]-l,2-dihydropyridine-3-carboxamide (77 mg, 66% ).
1H NMR (399.99 MHz, DMSO-D6) δ 9.08 (d, J= 4.8 Hz, IH)5 8.94 (s, IH), 7.92 (d, J= s 9.0 Hz, 2H), 7.83 (t, J= 7.8 Hz, IH), 7.73 (d, J= 8.0 Hz, IH), 7.40 (d, J= 8.5 Hz, 2H), 7.28 (d, J= 8.5 Hz, 2H), 4.38 (s, 2H), 2.81 (d, J= 4.8 Hz, 3H)5 2.22 (s, 3H);
APCI-MS m/z: 463.0 [MH+].
A solution of bromine (30 mg, 19 mmol) in acetic acid - THF was added dropwise to a o solution of 5-[(4-chlorophenyl)acetyl]-N,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]- l,2-dihydropyridine-3-carboxamide (75 mg, 0.162 mmol). After the addition, stirring was continued at RT overnight. The solvents were removed and the residue was purified on an Xterra C8 column using a gradient of acetonitrile/water. Freeze drying of the mixture afforded the title compound (86 mg, 95%). s 1H NMR (399.988 MHz5 CDCl3) δ 9.06 (m, 2H)5 7.84 (d, J= 7.8 Hz5 IH), 7.77 (q, J= 7.8 Hz5 IH)5 7.53 (t, J= 1.5 Hz, 2H), 7.47 - 7.35 (m, 4H), 6.27 (d, J= 3.4 Hz, IH), 2.96 (d, J= 5.0 Hz, 3H), 2.35 (s, 3H); APCI-MS m/z: 540.9 [MH+].
0
Human Neutrophil Elastase Quenched-FRET Assay
The assay uses Human Neutrophil Elastase (HNE) purified from serum (Calbiochem art.
324681; Ref. Baugh, RJ. et al, 1976, Biochemistry. 15, 836-841). HNE was stored in 5 50 mM sodium acetate (NaOAc), 200 mM sodium chloride (NaCl), pH 5.5 with added
30% glycerol at -200C. The protease substrate used was Elastase Substrate V Fluorogenic,
MeOSuc- AAPV-AMC (Calbiochem art. 324740; Ref. Castillo, MJ. et al., 1979, Anal.
Biochem. 99, 53-64). The substrate was stored in dimethyl sulphoxide (DMSO) at -200C.
The assay additions were as follows: Test compounds and controls were added to black 96- 0 well flat-bottom plates (Greiner 655076), 1 μL in 100% DMSO, followed by 30 μL HNE in assay buffer with 0.01% Triton (trade mark) X-100 detergent. The assay buffer constitution was: 100 mM Tris(hydroxymethyl)aminomethane (TRIS) (pH 7.5) and 500 mM NaCl. The enzyme and the compounds were incubated at room temperature for 15 minutes. Then 30 μl substrate in assay buffer was added. The assay was incubated for 30 minutes at room temperature. The concentrations of HNE enzyme and substrate during the incubation were 1.7 nM and 100 μM, respectively. The assay was then stopped by adding 60 μl stop solution (140 mM acetic acid, 200 mM sodium monochloroacetate, 60 mM sodium acetate, pH 4.3). Fluorescence was measured on a Wallac 1420 Victor 2 instrument at settings: Excitation 380 nm, Emission 460 nm. IC50 values were determined using Xlfit curve fitting using model 205.
When tested in the above screen, the compounds of the Examples gave IC50 values for inhibition of human neutrophil elastase activity of less than 30 μM (micromolar), indicating that the compounds of the invention are expected to possess useful therapeutic properties. Specimen results are shown in the following Table:
Figure imgf000055_0001

Claims

C L A I M S
1. A compound of formula (I)
Figure imgf000056_0001
(I)
wherein
R represents hydrogen or C i-Cβ alkyl;
W represents a 5-membered heterocyclic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group; and wherein the heterocyclic ring is optionally substituted by at least one substituent selected from halogen, C1-C4 alkyl, Cj- C4 alkoxy, CN, OH, NO2, C1-C3 alkyl substituted by one or more F atoms, C1-C3 alkoxy substituted by one or more F atoms, NR1V \ C≡CR15, CONR16R17, CHO, C2-C4
alkanoyl, S(O)xR18 and OSO2R19;
14
R represents phenyl or a 6-membered heteroaromatic ring comprising 1 to 3 ring nitrogen atoms; said ring being optionally substituted with at least one substituent selected from halogen, C1-C4 alkyl, C1-C4 alkoxy, CN, OH5 NO2, C1-C3 alkyl substituted by one or more F atoms, Ci -C3 alkoxy substituted by one or more F atoms, NR R , C≡CR , CONR31R32, CHO, C2-C4 alkanoyl, S(O)pR33 and OSO2R34; R , R , R and R independently represent H, Cj-Cg alkyl, formyl or C2-C6
10 11 12 13 alkanoyl; or the group -NR R or -NR R together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from O, S and NR26;
R and R independently represent H, C1-C3 alkyl or Si(CH3)3;
18 19 33 34
R , R , R and R independently represent H or C J-C3 alkyl; said alkyl being optionally substituted by one or more F atoms;
R represents H or F;
R represents phenyl or a five- or six-membered heteroaromatic ring containing 1 to 3 heteroatoms independently selected from O, S and N; said ring being optionally substituted with at least one substituent selected from halogen, Cj-Cg alkyl, cyano, Cj-Cg alkoxy, nitro, methylcarbonyl, NR R , CJ-C3 alkyl substituted by one or more F atoms or CJ-C3 alkoxy substituted by one or more F atoms;
R and R independently represent H or CJ-C3 alkyl; said alkyl being optionally further substituted by one or more F atoms;
4 R represents hydrogen or Cj-Cg alkyl optionally substituted with at least one substituent selected from fluoro, hydroxyl and Cj-Cg alkoxy;
24 X represents a single bond, O, NR or a group -Cj-Cg alkylene-Y-, wherein Y
24 represents a single bond, oxygen atom, NR or S(0)w; and said alkylene being optionally 51
further substituted by OH, halogen, CN, NR37R38, C1-C3 alkoxy, CONR39R40, CO2R66,
41 49 A^
SO2R and SO2NR R ;
4 4 or R and X are joined together such that the group -NR X together represents a 5 to 7 membered azacyclic ring optionally incorporating one further heteroatom selected from
4 444 45 46 O O,, SS aanndd NNRR ;; ssaaiidd rriinngg bbeeiinngg ooppttiioonnaallllyy ssuubbssttiittiuted by Cj-Cg alkyl or NR R ; said alkyl being optionally further substituted by OH;
either R represents a monocyclic ring system selected from i) phenoxy, ii) phenyl, iii) a 5- or 6-membered heteroaromatic ring comprising at least one ring heteroatom selected from nitrogen, oxygen and sulphur, iv) a saturated or partially unsaturated C3-Cg cycloalkyl ring, or v) a saturated or partially unsaturated 4- to 7-membered heterocyclic ring comprising at
20 least one ring heteroatom selected from oxygen, S(0)r and NR , wherein at least one of the ring carbon atoms may be optionally replaced by a carbonyl group,
or R represents a bicyclic ring system in which the two rings are independently selected from the monocyclic ring systems defined in ii), iii), iv) and v) above, wherein the two rings are either fused together, bonded directly to one another or are separated from one another by a linker group selected from oxygen, S(O)t or Cj-Cg alkylene optionally comprising one or more internal or terminal heteroatoms selected from oxygen, sulphur
27 and NR and being optionally substituted by at least one substituent selected from hydroxyl, oxo and Cj -Cg alkoxy,
the monocyclic or bicyclic ring system being optionally substituted by at least one
47 48 substituent selected from oxygen, CN5 OH5 Cj-Cg alkyl, Cj-Cg alkoxy, halogen, NR R , NO2, OSO2R , CO2R , C(=NH)NH2, C(O)NR R , C(S)NR R , SC(=NH)NH2, NR55C(=NH)NH2, S(O)VR21, SO2NR56R57, Ci-C3 alkoxy substituted by one or more F atoms and C1-C3 alkyl substituted by SO2R or by one or more F atoms; said Cj-Cg alkyl being optionally further substituted with at least one substituent selected from cyano, hydroxyl, Ci-C6 alkoxy, Ci-C6 alkylthio and -C(O)NR22R23;
or R may also represent H;
20
R represents hydrogen, Ci-C6 alkyl, Ci-C6 alkylcarbonyl or Ci-C6 alkoxycarbonyl;
21
R represents hydrogen, Ci-C6 alkyl or C3-Cs cycloalkyl; said alkyl or cycloalkyl group being optionally further substituted by one or more substituents selected independently from OH5 CN, C1-C3 alkoxy and CONR59R60;
37 38
R and R independently represent H, Ci-C6 alkyl, formyl or C2-C6 alkanoyl;
R and R independently represent H, Ci-C6 alkyl, formyl, C2-C6 alkanoyl, S(O)qR or SO2NR R ; said alkyl group being optionally further substituted by halogen, CN, Ci -C4 alkoxy or CONR64R65;
R and R independently represent H, Ci-C6 alkyl Or C3-C6 cycloalkyl;
p is 0, 1 or 2; q is 0, 1 or 2; r is 0, 1 or 2; t is 0, 1 or 2; w is 0, 1 or 2; x is 0, 1 or 2; v is 0, 1 or 2;
16 17 22 23 24 26 27 31 32 39 40 42 43 44 45 46 Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,Jv ,
R4', R50, R51, R52, R53, R54, R55, R56, R57, R58, R5', R60, R62, R63, R64, R65 and R66 each independently represent hydrogen or Q-Cg alkyl;
or a pharmaceutically acceptable salt thereof.
14 2. A compound according to Claim 1 , wherein the group R and the 2-pyridone ring are bonded to the 5-membered ring W in a 1,2-relationship.
3. A compound according to Claim 1 or Claim 2, wherein R represents a phenyl group substituted with one or two substituents independently selected from F5 Cl, CN, NO2 and
CF3.
14
4. A compound according to any one of Claims 1 to 3, wherein R represents a phenyl or pyridinyl group optionally substituted with one or two substituents independently selected from F, Cl, CN and CF3.
5. A compound according to any one of Claims 1 to 4, wherein R represents phenyl or
21 pyridinyl substituted by -S(O)VR wherein v represents the integer 2.
6. A compound according to any one of Claims 1 to 5, wherein X represents unsubstituted C1-C2 alkylene.
7. A compound according to any one of Claims 1 to 4 or Claim 6, wherein R represents H.
8. A compound of formula (I) as defined in Claim 1 selected from:
5 5-[l-(4-cyanophenyl)-lH-pyrazol-5-yl]-iV,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]- l,2-dihydropyridine-3-carboxamide;
5-[l-(4-cyanophenyl)-lΗ-pyrazol-5-yl]-6-methyl-N-[4-(methylsulfonyl)benzyl]-2-oxo-l-
[3-(trifluoromethyl)phenyl]-l,2-dihydropyridine-3-carboxamide;
5-[2-amino-5-(4-chlorophenyl)-l;,3-thiazol-4-yl]-iV,6-dimethyl-2-oxo-l-[3- o (trifluoromethyl)phenyl]-l ,2-dihydropyridine-3-carboxamide;
5-[4-(4-chloropb.enyl)-l,3-oxazol-5-yl]-N,6-dimethyl-2-oxo-l-[3-(trifluoromethyl)phenyl]- l,2-dihydropyridine-3-carboxamide;
5-[2-amino-5-(4-cyanophenyl)-l,3-thiazol-4-yl]-Ν,6-dimethyl-2-oxo-l-[3-
(trifluoromethyl)phenyl] - 1 ^-dihydropyridine-S-carboxamide; 5 1 -(3 -chloro-4-fiuoropheny l)-5 -[I -(4-cyanopheny I)- 1 H-pyrazol-5 -yl] -N,6-dimethy 1-2-oxo- l,2-dihydropyridine-3-carboxamide;
5-[2-(4-chloro-phenyl)-2H-pyrazol-3-yl]-6-methyl-2-oxo-l-(3-trifluoromethyl-phenyl)- l^-dihydro-pyridine-S-carboxylic acid methylamide;
5-[2-(4-fluoro-phenyl)-2H-pyrazol-3-yl]-6-methyl-2-oxo-l-(3-trifluoromethyl-phenyl)-l,2- o dihydro-pyridine-3-carboxylic acid methylamide;
5-[3-(4-cyano-phenyl)-3H-[l,2,3]triazol-4-yl]-6-methyl-2-oxo-l-(3-trifluoromethyl- phenyl)-l,2-dihydro-pyridine-3-carboxylic acid methylamide; and
5-[l-(4-cyanophenyl)-lΗ-l,2,4-triazol-5-yl]-N,6-dimethyl-2-oxo-l-[3-
(trifluoromethyl)phenyl]-l,2-dihydropyridme-3-carboxamide;
5 and pharmaceutically acceptable salts of any one thereof.
9. A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof as defined in claim 1 which comprises,
(a) reacting a compound of formula (II) 0
Figure imgf000062_0001
(N) wherein L represents a leaving group (such as halogen or hydroxyl) and R 5 R 5 R 3 R and
W are as defined in formula (I)5 with a compound of formula
HL S%. R N
R (III)
4 5 wherein X, R and R are as defined in formula (I); or
(b) reacting a compound of formula (IV)
Figure imgf000062_0002
(IV) wherein Hal represents a halogen atom and X5 R , R , R , R and R are as defined in formula (I)5 wwiitthh aa nnuucclleeiophile R -W-M wherein R and W are as defined in formula (I) and M represents an organo-tin or organo boronic acid group; or
(c) when W represents thiazolyl or oxazolyl, reacting a compound of formula (V)
Figure imgf000063_0001
(V)
1 3 4 5 6 14 wherein X, R , R , R , R , R and R are as defined in formula (I), with thiourea or formamide respectively; and optionally after (a), (b) or (c) carrying out one or more of the following:
• converting the compound obtained to a further compound of the invention
• forming a pharmaceutically acceptable salt of the compound.
10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 in association with a pharmaceutically acceptable adjuvant, diluent or carrier.
11. A process for the preparation of a pharmaceutical composition as claimed in claim 10 which comprises mixing a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 with a pharmaceutically acceptable adjuvant, diluent or carrier.
12. A compound of formula (I) or a pharmaceutically-acceptable salt thereof as claimed in any one of claims 1 to 8 for use in therapy.
13. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for the treatment of human diseases or conditions in which modulation of neutrophil elastase activity is beneficial.
14. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8 in the manufacture of a medicament for use in treating adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury.
15. A method of treating, or reducing the risk of, a disease or condition in which inhibition of neutrophil elastase activity is beneficial which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8.
16. A method of treating, or reducing the risk of, an inflammatory disease or condition which comprises administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof as claimed in any one of claims 1 to 8.
17. A method according to Claim 15 or Claim 16, wherein the disease or condition is adult respiratory distress syndrome (ARDS), cystic fibrosis, pulmonary emphysema, bronchitis including chronic bronchitis, bronchiectasis, chronic obstructive pulmonary disease (COPD), pulmonary hypertension, asthma including refractive asthma, rhinitis, psoriasis, ischemia-reperfusion injury, rheumatoid arthritis, osteoarthritis, systemic inflammatory response syndrome (SIRS), chronic wound, cancer, atherosclerosis, peptic ulcers, Crohn's disease, ulcerative colitis or gastric mucosal injury.
PCT/SE2007/000441 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. WO2007129962A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
DE602007005120T DE602007005120D1 (en) 2006-05-08 2007-05-07 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF DISEASES OR SUFFERINGS WHICH ARE OF AN INHIBITION FOR THE ACTIVITY OF NEUTROPHIL ELASTASE
US12/299,879 US7998984B2 (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
JP2009509485A JP2009536196A (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of diseases or conditions where inhibition of neutrophil elastase activity is beneficial
CA002649813A CA2649813A1 (en) 2006-05-08 2007-05-07 A system for wireless transmission of measurement results intended to be used in a coupling device and a use of the system in a vehicle
MX2008013836A MX2008013836A (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
AU2007248950A AU2007248950B2 (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
BRPI0711357-9A BRPI0711357A2 (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of human neutrophil elastase activity is beneficial
AT07748105T ATE459615T1 (en) 2006-05-08 2007-05-07 2-PYRIDONE DERIVATIVES FOR THE TREATMENT OF ILLNESSES OR CONDITIONS IN WHICH INHIBITION OF NEUTROPHIL ELASTASE ACTIVITY IS BENEFICIAL
EP07748105A EP2018375B1 (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
IL194948A IL194948A0 (en) 2006-05-08 2008-10-27 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
NO20084872A NO20084872L (en) 2006-05-08 2008-11-19 2-pyridone derivatives for the treatment of disease or conditions where inhibition of neutrophil elastase activity is beneficial
HK09106680.3A HK1127599A1 (en) 2006-05-08 2009-07-22 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79878606P 2006-05-08 2006-05-08
US60/798,786 2006-05-08

Publications (1)

Publication Number Publication Date
WO2007129962A1 true WO2007129962A1 (en) 2007-11-15

Family

ID=38667997

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2007/000441 WO2007129962A1 (en) 2006-05-08 2007-05-07 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.

Country Status (21)

Country Link
US (1) US7998984B2 (en)
EP (1) EP2018375B1 (en)
JP (1) JP2009536196A (en)
KR (1) KR20090017573A (en)
CN (1) CN101490033A (en)
AR (1) AR060875A1 (en)
AT (1) ATE459615T1 (en)
AU (1) AU2007248950B2 (en)
BR (1) BRPI0711357A2 (en)
CA (1) CA2649813A1 (en)
CL (1) CL2007001282A1 (en)
DE (1) DE602007005120D1 (en)
ES (1) ES2339607T3 (en)
HK (1) HK1127599A1 (en)
IL (1) IL194948A0 (en)
MX (1) MX2008013836A (en)
NO (1) NO20084872L (en)
TW (1) TW200808763A (en)
UY (1) UY30328A1 (en)
WO (1) WO2007129962A1 (en)
ZA (1) ZA200809024B (en)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110132A1 (en) 2008-04-20 2009-10-21 Firma D20 Biosience Group Ltd. Use of deuterium oxide as elastase inhibitor
WO2011039528A1 (en) 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
US8063073B2 (en) 2003-09-18 2011-11-22 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
DE102010030187A1 (en) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft New 4-cyano-2-sulfonylphenyl-pyrazolyl-substituted pyridinones and pyrazinones compounds are human neutrophil elastase inhibitors, useful to treat and prevent e.g. pulmonary arterial hypertension and chronic obstructive pulmonary disease
WO2012002502A1 (en) * 2010-06-30 2012-01-05 大日本住友製薬株式会社 Dihydropyrimidinone derivative and pharmaceutical use thereof
US8114881B2 (en) 2006-05-08 2012-02-14 Astrazeneca Ab 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
US8232296B2 (en) 2009-02-20 2012-07-31 Astrazeneca Ab Salt 628
WO2013018804A1 (en) 2011-08-01 2013-02-07 大日本住友製薬株式会社 Uracil derivative and use thereof for medical purposes
US8466284B2 (en) 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
US8609147B2 (en) 2007-07-05 2013-12-17 D2 Bioscience Group Ltd. Use of deuterium oxide for treatment of herpes virus-based diseases of the skin
WO2014029830A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
WO2014029831A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
WO2014029832A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
US8709496B2 (en) 2009-01-07 2014-04-29 D2 Bioscience Group Ltd. Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
WO2016096638A1 (en) * 2014-12-15 2016-06-23 Chiesi Farmaceutici S.P.A. Novel compounds
WO2021053058A1 (en) 2019-09-17 2021-03-25 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
WO2021209740A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
US7879846B2 (en) * 2006-09-21 2011-02-01 Kyorin Pharmaceutical Co.., Ltd. Serine hydrolase inhibitors
TWI546537B (en) * 2009-05-19 2016-08-21 維維亞生技公司 Methods for providing personalized medicine tests ex vivo for hematological neoplasms
UY36875A (en) 2015-09-02 2017-03-31 Glaxosmithkline Intellectual Property (No 2) Ltd BROMODOMINIUM INHIBITING COMPOSITIONS FOR THE TREATMENT OF VARIOUS DISEASES
CN106674098B (en) * 2016-12-23 2019-07-02 中国医科大学 N- (3- cyano -4- alkoxyl phenyl) pyridine carboxamides and application thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300396A1 (en) 2000-06-12 2003-04-09 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
WO2004020410A2 (en) 2002-08-27 2004-03-11 Bayer Healthcare Ag Dihydropyridinone derivatives as hne inhibitors
WO2004043924A1 (en) 2002-11-12 2004-05-27 Astrazeneca Ab 2-pyridone derivatives as inhibitors of neutrophile elastase
WO2005021509A1 (en) 2003-08-28 2005-03-10 Astrazeneca Ab Quinoline derivatives as neutrophil elastase inhibitors and their use
WO2005026123A1 (en) 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
WO2005026124A1 (en) 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as netrophil elastase inhibitors and their use
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
WO2006098684A1 (en) 2005-03-16 2006-09-21 Astrazeneca Ab Novel compounds ii 2-pyridine derivatives as inhibitors of neutrophile elastase.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1067079A (en) * 1976-07-22 1979-11-27 Yamanouchi Pharmaceutical Co. Nitrogen-containing heterobicyclic compounds
DE2706977A1 (en) * 1977-02-18 1978-08-24 Hoechst Ag BENZOESAEURS AND THEIR DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
EP0008864A1 (en) 1978-08-15 1980-03-19 FISONS plc Pyridopyrazine and quinoxaline derivatives, processes for their preparation, and pharmaceutical compositions containing them
JPH02152966A (en) 1988-12-05 1990-06-12 Otsuka Pharmaceut Co Ltd 4-hydroxycarbostyril derivative
US5521179A (en) * 1991-04-18 1996-05-28 Zeneca Limited Heterocyclic amides
US5441960A (en) * 1992-04-16 1995-08-15 Zeneca Limited 1-pyrimidinylacetamide human leukocyte elastate inhibitors
EP0948496A2 (en) 1996-12-05 1999-10-13 Amgen inc. Substituted pyrimidinone and pyridone compounds and methods of use
JPH1171351A (en) * 1997-08-29 1999-03-16 Ss Pharmaceut Co Ltd Substituted quinolone derivative and medicine containing the same
KR20030070082A (en) 2000-12-28 2003-08-27 시오노기세이야쿠가부시키가이샤 Pyridone derivative having affinity for cannabinoid 2-type receptor
WO2003015798A1 (en) 2001-08-14 2003-02-27 Toyama Chemical Co., Ltd. Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue
GB0129260D0 (en) * 2001-12-06 2002-01-23 Eisai London Res Lab Ltd Pharmaceutical compositions and their uses
GB2383326A (en) 2001-12-20 2003-06-25 Bayer Ag Antiinflammatory dihydropyridines
MXPA03000145A (en) * 2002-01-07 2003-07-15 Pfizer Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators.
WO2003070277A1 (en) 2002-02-19 2003-08-28 Shionogi & Co., Ltd. Antipruritics
GB2392910A (en) 2002-09-10 2004-03-17 Bayer Ag 2-Oxopyrimidine derivatives and their use as human leukocyte elastase inhibitors
SE0302324D0 (en) * 2003-08-28 2003-08-28 Astrazeneca Ab Novel compounds
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
KR200365249Y1 (en) * 2004-07-28 2004-10-21 추윤정 An electric puff
GB0420722D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Substituted Amid derivatives & methods of use
GB0512940D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Compounds and their use
GB0605469D0 (en) 2006-03-17 2006-04-26 Argenta Discovery Ltd Multimers of heterocyclic compounds and their use
BRPI0711169A2 (en) 2006-05-04 2011-08-23 Argenta Discovery Ltd tetrahydropyrrolopyridinediones and their use as human neutrophil elastase inhibitors
TW200808763A (en) 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds I
TW200808771A (en) * 2006-05-08 2008-02-16 Astrazeneca Ab Novel compounds II
EP2064184A1 (en) 2006-09-04 2009-06-03 AstraZeneca AB Multimeric heterocyclic compounds useful as neutrophil elastase inhibitors
WO2008104752A1 (en) 2007-02-26 2008-09-04 Astrazeneca Ab Dihydropyridones as elastase inhibitors
WO2009058076A1 (en) 2007-11-02 2009-05-07 Astrazeneca Ab 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
CL2008003301A1 (en) 2007-11-06 2009-10-16 Astrazeneca Ab Compounds derived from 3,4-dihydropyrazine-2-carboxamide, inhibitors of elastase of human neutrophils; pharmaceutical compositions; compounding and pharmaceutical composition processes; and use in the treatment of respiratory distress syndrome in adults, cystic fibrosis, cancer, among others.
TW201036957A (en) * 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1300396A1 (en) 2000-06-12 2003-04-09 Eisai Co., Ltd. 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
WO2004020410A2 (en) 2002-08-27 2004-03-11 Bayer Healthcare Ag Dihydropyridinone derivatives as hne inhibitors
WO2004043924A1 (en) 2002-11-12 2004-05-27 Astrazeneca Ab 2-pyridone derivatives as inhibitors of neutrophile elastase
WO2005021509A1 (en) 2003-08-28 2005-03-10 Astrazeneca Ab Quinoline derivatives as neutrophil elastase inhibitors and their use
WO2005026123A1 (en) 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
WO2005026124A1 (en) 2003-09-18 2005-03-24 Astrazeneca Ab 2-pyridone derivatives as netrophil elastase inhibitors and their use
WO2005080372A1 (en) 2004-02-19 2005-09-01 Bayer Healthcare Ag Dihydropyridinone derivatives
WO2006098684A1 (en) 2005-03-16 2006-09-21 Astrazeneca Ab Novel compounds ii 2-pyridine derivatives as inhibitors of neutrophile elastase.
WO2006098683A1 (en) 2005-03-16 2006-09-21 Astrazeneca Ab 2-pyridine derivatives as inhibitors of neutrophile elastase

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ADEYEMI ET AL., GUT, vol. 26, 1985, pages 1306 - 1311
ADEYEMI ET AL., RHEUMATOL. INT., vol. 6, 1986, pages 57
KAKIMOTO ET AL., CELLULAR IMMUNOL., vol. 165, 1995, pages 26 - 32
KISHIMA ET AL., ANN. THORAC. SURG., vol. 65, 1998, pages 913 - 918
SHIMAKURA ET AL., BRAIN RESEARCH, vol. 858, 2000, pages 55 - 60
TIEFENBACHER ET AL., EUR. J. PHYSIOL., vol. 433, 1997, pages 563 - 570
WRIGHT ET AL., AM. J. RESPIR. CRIT. CARE MED., vol. 166, 2002, pages 954 - 960

Cited By (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8063073B2 (en) 2003-09-18 2011-11-22 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
US8501784B2 (en) 2003-09-18 2013-08-06 Astrazeneca Ab 2-pyridone derivatives as neutrophil elastase inhibitors and their use
US8114881B2 (en) 2006-05-08 2012-02-14 Astrazeneca Ab 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
US8609147B2 (en) 2007-07-05 2013-12-17 D2 Bioscience Group Ltd. Use of deuterium oxide for treatment of herpes virus-based diseases of the skin
US8466284B2 (en) 2007-11-06 2013-06-18 Astra Zeneca Ab Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
EP2508189A3 (en) * 2008-04-20 2012-11-07 D2 Bioscience Group Ltd Use of deuterium oxide as elastase inhibitor
WO2009130615A2 (en) * 2008-04-20 2009-10-29 D2O Bioscience Group Ltd. Use of deuterium oxide as an elastase inhibitor
WO2009130615A3 (en) * 2008-04-20 2010-03-18 D2O Bioscience Group Ltd. Use of deuterium oxide as an elastase inhibitor
EP2110132A1 (en) 2008-04-20 2009-10-21 Firma D20 Biosience Group Ltd. Use of deuterium oxide as elastase inhibitor
US8709496B2 (en) 2009-01-07 2014-04-29 D2 Bioscience Group Ltd. Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tract
US8232296B2 (en) 2009-02-20 2012-07-31 Astrazeneca Ab Salt 628
JP2013506649A (en) * 2009-10-02 2013-02-28 アストラゼネカ・アクチエボラーグ 2-pyridone compounds used as inhibitors of neutrophil elastase
WO2011039528A1 (en) 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
DE102010030187A1 (en) 2010-06-16 2011-12-22 Bayer Schering Pharma Aktiengesellschaft New 4-cyano-2-sulfonylphenyl-pyrazolyl-substituted pyridinones and pyrazinones compounds are human neutrophil elastase inhibitors, useful to treat and prevent e.g. pulmonary arterial hypertension and chronic obstructive pulmonary disease
WO2012002502A1 (en) * 2010-06-30 2012-01-05 大日本住友製薬株式会社 Dihydropyrimidinone derivative and pharmaceutical use thereof
WO2013018804A1 (en) 2011-08-01 2013-02-07 大日本住友製薬株式会社 Uracil derivative and use thereof for medical purposes
WO2014029831A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
WO2014029832A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
WO2014029830A1 (en) 2012-08-23 2014-02-27 Boehringer Ingelheim International Gmbh Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activity
WO2016096638A1 (en) * 2014-12-15 2016-06-23 Chiesi Farmaceutici S.P.A. Novel compounds
US9409870B2 (en) 2014-12-15 2016-08-09 Chiesi Farmaceutici S.P.A. Compounds
US11666888B2 (en) 2018-02-05 2023-06-06 Bio-Rad Laboratories, Inc. Chromatography resin having an anionic exchange-hydrophobic mixed mode ligand
WO2021053058A1 (en) 2019-09-17 2021-03-25 Mereo Biopharma 4 Limited Alvelestat for use in the treatment of graft rejection, bronchiolitis obliterans syndrome and graft versus host disease
WO2021209740A1 (en) 2020-04-16 2021-10-21 Mereo Biopharma 4 Limited Methods involving neutrophil elastase inhibitor alvelestat for treating coronavirus infection
WO2023067103A1 (en) 2021-10-20 2023-04-27 Mereo Biopharma 4 Limited Neutrophil elastase inhibitors for use in the treatment of fibrosis

Also Published As

Publication number Publication date
IL194948A0 (en) 2009-08-03
US7998984B2 (en) 2011-08-16
CL2007001282A1 (en) 2008-01-18
ZA200809024B (en) 2010-03-31
EP2018375A1 (en) 2009-01-28
AU2007248950B2 (en) 2010-11-18
AR060875A1 (en) 2008-07-16
TW200808763A (en) 2008-02-16
DE602007005120D1 (en) 2010-04-15
BRPI0711357A2 (en) 2011-09-27
NO20084872L (en) 2009-02-03
UY30328A1 (en) 2008-01-02
AU2007248950A1 (en) 2007-11-15
CN101490033A (en) 2009-07-22
CA2649813A1 (en) 2007-11-15
ATE459615T1 (en) 2010-03-15
MX2008013836A (en) 2008-11-10
KR20090017573A (en) 2009-02-18
HK1127599A1 (en) 2009-10-02
ES2339607T3 (en) 2010-05-21
US20090131486A1 (en) 2009-05-21
EP2018375B1 (en) 2010-03-03
JP2009536196A (en) 2009-10-08

Similar Documents

Publication Publication Date Title
EP2018375B1 (en) 2-pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial.
AU2010236027B2 (en) 2-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial
AU2008325288B2 (en) Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
US8436024B2 (en) 2-pyridone compounds
WO2009058076A1 (en) 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase
WO2008104752A1 (en) Dihydropyridones as elastase inhibitors
EP1966187A1 (en) Piperazine compounds useful as antagonists of c-c chemokines (ccr2b and ccr5) for the treatment of inflammatory diseases

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780025907.1

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07748105

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007248950

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2649813

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 572260

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 194948

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/013836

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 9240/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009509485

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007248950

Country of ref document: AU

Date of ref document: 20070507

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2007748105

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1020087029811

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 12299879

Country of ref document: US

ENP Entry into the national phase

Ref document number: PI0711357

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20081107